<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Matthew Arnold &#38; Baldwin LLP &#124; Giving you a lot more than just law... &#187; News</title>
	<atom:link href="http://www.mablaw.com/category/Sectors/news/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.mablaw.com</link>
	<description>MAB</description>
	<lastBuildDate>Mon, 21 May 2012 13:34:52 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
		<item>
		<title>Royal Pharmaceutical Society calls for change in EU law to prohibit export of drugs where it endangers health</title>
		<link>http://www.mablaw.com/2012/05/royal-pharmaceutical-society-medicine-shortage/</link>
		<comments>http://www.mablaw.com/2012/05/royal-pharmaceutical-society-medicine-shortage/#comments</comments>
		<pubDate>Fri, 18 May 2012 18:08:21 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[International]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[All Party Pharmacy Group]]></category>
		<category><![CDATA[APPG]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[exporter]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[importer]]></category>
		<category><![CDATA[Kevin Barron]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[medicine supply shortage]]></category>
		<category><![CDATA[medicines]]></category>
		<category><![CDATA[parallel export]]></category>
		<category><![CDATA[parallel exporting]]></category>
		<category><![CDATA[parallel import]]></category>
		<category><![CDATA[parallel importing]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>
		<category><![CDATA[pharmacies]]></category>
		<category><![CDATA[pharmacy]]></category>
		<category><![CDATA[Royal Pharmaceutical Society]]></category>
		<category><![CDATA[RPS]]></category>
		<category><![CDATA[Wholesale]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19988</guid>
		<description><![CDATA[The chair of the Royal Pharmaceutical Society, Lindsey Gilpin, has called for a change to the European Union laws that permit parallel exporting of products – ie the purchase of drugs from one cheaper country into another more expensive one to make a profit because of the price differences. Ms Gilpin would like to see [...]]]></description>
			<content:encoded><![CDATA[<p>The chair of the Royal Pharmaceutical Society, Lindsey Gilpin, has called for a change to the European Union laws that permit parallel exporting of products – ie the purchase of drugs from one cheaper country into another more expensive one to make a profit because of the price differences. Ms Gilpin would like to see an exemption to the EU law when patients’ lives are threatened. The weak pound has led to legitimate opportunism from some to make a profit on the drugs in the UK’s supply chain, but this has meant that pharmacies – and more importantly patients – do not always receive the drugs when they need. The seriousness of this issue was highlighted in the Parliamentary All Party Pharmacy Group’s report following its enquiry.</p>
<p>Ms Gilpin said that medicine is there to save lives and should not be treated just like any other product that can be bought and sold for a profit. She called for a change in the law to place public health protection above profit. She also bemoaned the fact that pharmacies are spending too much time trying to source drugs because of the problem. She said she should be spending that time helping patients instead.</p>
<p>Matthew Arnold &amp; Baldwin LLP, in association with the Watford Chamber of Commerce, Sigma Pharmaceuticals and the Independent Pharmacy Federation, are holding a seminar on the medicine shortage crisis on 25 June with Kevin Barron, the APPG’s chair, speaking.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/royal-pharmaceutical-society-medicine-shortage/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Divorce and the blame game: is it time to for the &#8216;no-fault&#8217; divorce?</title>
		<link>http://www.mablaw.com/2012/05/divorce-and-the-blame-game-is-it-time-to-for-the-no-fault-divorce/</link>
		<comments>http://www.mablaw.com/2012/05/divorce-and-the-blame-game-is-it-time-to-for-the-no-fault-divorce/#comments</comments>
		<pubDate>Fri, 18 May 2012 15:14:31 +0000</pubDate>
		<dc:creator>Amanda Melton</dc:creator>
				<category><![CDATA[Children's Issues]]></category>
		<category><![CDATA[Divorce]]></category>
		<category><![CDATA[Living Together]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Unhappily Married]]></category>
		<category><![CDATA[Nicholas Wall]]></category>
		<category><![CDATA[no-fault]]></category>
		<category><![CDATA[Separation]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19977</guid>
		<description><![CDATA[I have recently written an article on the possible introduction of ‘no-fault’ divorces, which was published in The Lawyer magazine. Sir Nicholas Wall, the country’s most senior family law judge, has argued that the courts should no longer have to allocate blame for the failure of a marriage. Certainly, ‘no-fault’ divorces would help to maintain [...]]]></description>
			<content:encoded><![CDATA[<p>I have recently written an article on the possible introduction of ‘no-fault’ divorces, which was published in <em>The Lawyer</em> magazine.</p>
<p>Sir Nicholas Wall, the country’s most senior family law judge, has argued that the courts should no longer have to allocate blame for the failure of a marriage. Certainly, ‘no-fault’ divorces would help to maintain the mediation-based approach that family lawyers have worked hard to develop.</p>
<p>Please click <a href="http://www.thelawyer.com/divorce-the-blame-game/1012117.article">here</a> to read the article.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/divorce-and-the-blame-game-is-it-time-to-for-the-no-fault-divorce/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NICE to be stripped of role of directing NHS on cost-effectiveness of drugs</title>
		<link>http://www.mablaw.com/2012/05/nice-nhs-cost-drugs/</link>
		<comments>http://www.mablaw.com/2012/05/nice-nhs-cost-drugs/#comments</comments>
		<pubDate>Fri, 18 May 2012 11:49:36 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[National Health Service]]></category>
		<category><![CDATA[National Institute for Health and Clinical Excellence]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>
		<category><![CDATA[value based pricing]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19985</guid>
		<description><![CDATA[The National Institute for Health and Clinical Excellence (NICE) will be stripped of its current role of directing the National Health Service on the cost-effectiveness of drugs. NICE’s rule will be replaced by the new value-based pricing system that will be introduced in January 2014. This is according to a statement from Andrew Lansley, the [...]]]></description>
			<content:encoded><![CDATA[<p>The National Institute for Health and Clinical Excellence (NICE) will be stripped of its current role of directing the National Health Service on the cost-effectiveness of drugs. NICE’s rule will be replaced by the new value-based pricing system that will be introduced in January 2014. This is according to a statement from Andrew Lansley, the Health Secretary. NICE will still look at the cost-effectiveness of drugs but it will no longer be able to make decisions. The Department of Health will discuss price negotiations with the pharma industry in the second half of 2012 in the lead up to the change. For now, there is uncertainty with purchasers concerned that drug prices will rise and suppliers worried that they will be squeezed on price.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/nice-nhs-cost-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Claims of long trading history ruled to be misleading – Coys of Kensington Automobiles v ASA, High Court</title>
		<link>http://www.mablaw.com/2012/05/advertising-claims-long-trading-history-misleading/</link>
		<comments>http://www.mablaw.com/2012/05/advertising-claims-long-trading-history-misleading/#comments</comments>
		<pubDate>Thu, 17 May 2012 17:37:39 +0000</pubDate>
		<dc:creator>Simon Weinberg</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[advert]]></category>
		<category><![CDATA[Advertising Standards Authority]]></category>
		<category><![CDATA[CAP code]]></category>
		<category><![CDATA[High Court]]></category>
		<category><![CDATA[judicial review]]></category>
		<category><![CDATA[misleading advertising]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19974</guid>
		<description><![CDATA[The High Court has upheld an Advertising Standards Authority that someone trading as “Coys” who had claimed to have been “trading since 1919” was misleading, given that the current business had not been in business for more than a few years and there had been several liquidations and a number of forms of business trading [...]]]></description>
			<content:encoded><![CDATA[<p>The High Court has upheld an Advertising Standards Authority that someone trading as “Coys” who had claimed to have been “trading since 1919” was misleading, given that the current business had not been in business for more than a few years and there had been several liquidations and a number of forms of business trading under the name “Coys” since 1919.</p>
<p><a href="http://www.asa.org.uk/ASA-action/Adjudications/2010/9/Coys-of-Kensington-Automobiles-Ltd/TF_ADJ_49064.aspx">In 2010, the ASA ruled that Coys of Kensington Automobiles (Coys) had breached the CAP Code</a>. The CAP Code is the code of practice that seeks to ensure that adverts are not misleading. Although the CAP Code does not have legal force, it is best practice to comply with it, as failure to do so can result in bad publicity and ultimately an inability to obtain advertising space.</p>
<p>The ASA had ruled that the claims of a long trading history indicated to customers that the business was financially stable, particularly in the used-car industry in which Coys traded, and that those claims were misleading given the reality of the trading history. The current corporate form of the business had been created in 2003 and only began trading in 2004.</p>
<p>Coys brought a claim for judicial review of the ASA’s ruling, whereby the High Court was asked to ensure that the ASA’s ruling was lawful and fair. Coys had claimed that the ASA’s original ruling was “irrational” (one of the grounds for applying for a judicial review), arguing that no reasonable authority could have concluded that Coys’ advertising claims indicated any form of financial stability. Coys accepted that the ASA’s ruling was in accordance with the relevant guidance on the CAP Code, but argued that the guidance itself was irrational.</p>
<p>The High Court ruled in favour of the ASA and upheld the ASA’s ruling, stating that the guidance on the CAP Code had been put together by experts in the advertising industry and could not be argued to be irrational. The High Court’s ruling also shows that an advertiser making claims of a long trading history needs to be able to produce evidence of financial stability; in this case, particularly with the repeated liquidations that the “business” had experienced, such a claim was misleading and the ASA’s ruling was correct.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/advertising-claims-long-trading-history-misleading/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Consumer contract must clearly state rights to unilaterally vary fees and terminate – Nemzeti v Invitel, European Court of Justice</title>
		<link>http://www.mablaw.com/2012/05/consumer-contract-nemzeti-invitel/</link>
		<comments>http://www.mablaw.com/2012/05/consumer-contract-nemzeti-invitel/#comments</comments>
		<pubDate>Thu, 17 May 2012 17:32:44 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Commercial Contracts]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[agreements]]></category>
		<category><![CDATA[CJEU]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[consumer agreement]]></category>
		<category><![CDATA[consumer agreements]]></category>
		<category><![CDATA[consumer contract]]></category>
		<category><![CDATA[consumer contracts]]></category>
		<category><![CDATA[consumer law]]></category>
		<category><![CDATA[consumer laws]]></category>
		<category><![CDATA[contract]]></category>
		<category><![CDATA[contracts]]></category>
		<category><![CDATA[Court of Justice of European Union]]></category>
		<category><![CDATA[Court of Justice of the European Union]]></category>
		<category><![CDATA[ECJ]]></category>
		<category><![CDATA[European Court of Justice]]></category>
		<category><![CDATA[fair]]></category>
		<category><![CDATA[fairness]]></category>
		<category><![CDATA[unenforceable]]></category>
		<category><![CDATA[unfair]]></category>
		<category><![CDATA[unfair terms]]></category>
		<category><![CDATA[Unfair Terms Directive]]></category>
		<category><![CDATA[Unfair Terms in Consumer Contracts Directive]]></category>
		<category><![CDATA[Unfair Terms in Consumer Contracts Regulation 1999]]></category>
		<category><![CDATA[Unfair Terms in Consumer Contracts Regulations]]></category>
		<category><![CDATA[unfair terms in consumer contracts regulations 1999]]></category>
		<category><![CDATA[unfairness]]></category>
		<category><![CDATA[unilateral right]]></category>
		<category><![CDATA[void]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19982</guid>
		<description><![CDATA[Where a consumer contract provides for a supplier to unilaterally vary fees and the law gives the consumer the right to terminate the contract if that happens, the supplier must state that right in plain and intelligible language. If not, the court may take that into account when determining whether the consumer contract term is [...]]]></description>
			<content:encoded><![CDATA[<p>Where a consumer contract provides for a supplier to unilaterally vary fees and the law gives the consumer the right to terminate the contract if that happens, the supplier must state that right in plain and intelligible language. If not, the court may take that into account when determining whether the consumer contract term is unfair. Even if the consumer’s right is mandatory, the supplier should still provide that to the consumer in plain, intelligible language. This is what the European Court of Justice has ruled in a case that had been referred to it by a Hungarian court, but the result – which conforms with what the Office of Fair Trading had always believed to be the case – applies in the UK too.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/consumer-contract-nemzeti-invitel/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bristol Myers Squibb loses one third of its revenue overnight as Plavix the latest blockbuster drug to fall over the patent cliff</title>
		<link>http://www.mablaw.com/2012/05/bristol-myers-squibb-plavix-patent-cliff/</link>
		<comments>http://www.mablaw.com/2012/05/bristol-myers-squibb-plavix-patent-cliff/#comments</comments>
		<pubDate>Thu, 17 May 2012 17:01:27 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[Inventions]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[big pharma]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Intellectual property]]></category>
		<category><![CDATA[intellectual property rights]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[patent]]></category>
		<category><![CDATA[patent cliff]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma product]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical patent]]></category>
		<category><![CDATA[pharmaceutical patents]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19970</guid>
		<description><![CDATA[Bristol Myers Squibb has lost one third of its revenues overnight, as its anti-platelet therapy, Plavix, has become the latest blockbuster drug of the big pharma companies to see its patent expire. This is part of the process known as the patent cliff – where big pharma companies are losing widely-used patented products in their [...]]]></description>
			<content:encoded><![CDATA[<p>Bristol Myers Squibb has lost one third of its revenues overnight, as its anti-platelet therapy, Plavix, has become the latest blockbuster drug of the big pharma companies to see its patent expire. This is part of the process known as the patent cliff – where big pharma companies are losing widely-used patented products in their droves between 2011 and 2016 without sufficient replacements to fund their size and research and development programmes. BMS has said that it will not make the mistake that Pfizer did when it lost the patent for Lipitor a few months ago and market the product extensively after the end of the patent life. That was a fight that Pfizer ultimately conceded. BMS has accepted that there are too many generics companies already waiting in the wings and BMS is therefore going to lose US$7bn of revenue overnight.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/bristol-myers-squibb-plavix-patent-cliff/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>High Court orders that The Pirate Bay should be blocked</title>
		<link>http://www.mablaw.com/2012/05/high-court-orders-that-the-pirate-bay-should-be-blocked/</link>
		<comments>http://www.mablaw.com/2012/05/high-court-orders-that-the-pirate-bay-should-be-blocked/#comments</comments>
		<pubDate>Thu, 17 May 2012 15:17:56 +0000</pubDate>
		<dc:creator>Simon Weinberg</dc:creator>
				<category><![CDATA[Film Studios]]></category>
		<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Online]]></category>
		<category><![CDATA[TV & Radio]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[Websites]]></category>
		<category><![CDATA[BPI]]></category>
		<category><![CDATA[British Phonographic Industry]]></category>
		<category><![CDATA[copyright]]></category>
		<category><![CDATA[copyright infringement]]></category>
		<category><![CDATA[Everything Everywhere]]></category>
		<category><![CDATA[file-sharing]]></category>
		<category><![CDATA[High Court]]></category>
		<category><![CDATA[illegal]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[Intellectual property]]></category>
		<category><![CDATA[intellectual property rights]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[Internet service provider]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[ISP]]></category>
		<category><![CDATA[O2]]></category>
		<category><![CDATA[online content]]></category>
		<category><![CDATA[Phonographic Performance Ltd]]></category>
		<category><![CDATA[PPL]]></category>
		<category><![CDATA[Sky]]></category>
		<category><![CDATA[TalkTalk]]></category>
		<category><![CDATA[The Pirate Bay]]></category>
		<category><![CDATA[unauthorised]]></category>
		<category><![CDATA[unlawful]]></category>
		<category><![CDATA[Virgin Media]]></category>
		<category><![CDATA[web]]></category>
		<category><![CDATA[web site]]></category>
		<category><![CDATA[web sites]]></category>
		<category><![CDATA[Website]]></category>
		<category><![CDATA[website content]]></category>
		<category><![CDATA[websites]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19972</guid>
		<description><![CDATA[The High Court recently ruled that both the operators and users of The Pirate Bay file-sharing website were guilty of infringing copyright. That ruling came in response to an application by a number of record companies, represented by the BPI (the British Phonographic Industry) and PPL (Phonographic Performance Ltd), for an order for Internet service [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.mablaw.com/2012/03/pirate-bay-dramatico-entertainment-british-sky-broadcasting/">The High Court recently ruled that both the operators and users of The Pirate Bay file-sharing website were guilty of infringing copyright.</a> That ruling came in response to an application by a number of record companies, represented by the BPI (the British Phonographic Industry) and PPL (Phonographic Performance Ltd), for an order for Internet service providers (ISPs) to block, or at least impede, access to The Pirate Bay.</p>
<p>The High Court has now granted that order. Virgin Media, Sky, Everything Everywhere, O2 and TalkTalk have been ordered by the High Court to put measures in place that prevent their respective users accessing The Pirate Bay. ISPs have criticised the move as a part-solution only to the increasing problem of copyright infringement.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/high-court-orders-that-the-pirate-bay-should-be-blocked/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Abiraterone drug approval granted by NICE – but at what price?</title>
		<link>http://www.mablaw.com/2012/05/abiraterone-drug-nice/</link>
		<comments>http://www.mablaw.com/2012/05/abiraterone-drug-nice/#comments</comments>
		<pubDate>Wed, 16 May 2012 06:45:21 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Inventions]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[drug approval]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[innovate]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[medicines]]></category>
		<category><![CDATA[National Health Service]]></category>
		<category><![CDATA[National Institute for Health and Clinical Excellence]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma product]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>
		<category><![CDATA[QIPP]]></category>
		<category><![CDATA[QIPP Agenda]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[research and development]]></category>
		<category><![CDATA[value based pricing]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19956</guid>
		<description><![CDATA[Abiraterone, the new drug that extends the lives of people with advanced prostate cancer by three months, has been approved by the National Institute for Health and Clinical Excellence (NICE). This follows an earlier rejection by the drug approval body for the National Health Service, on the basis that it was not cost-effective for the [...]]]></description>
			<content:encoded><![CDATA[<p>Abiraterone, the new drug that extends the lives of people with advanced prostate cancer by three months, has been approved by the National Institute for Health and Clinical Excellence (NICE). This follows an earlier rejection by the drug approval body for the National Health Service, on the basis that it was not cost-effective for the NHS, given the value for money that it brought. NICE claims that it has now seen more evidence of the benefits provided by the drug. But tellingly there has also been a reduction in the price charged to the NHS by Janssen, the drug manufacturer.</p>
<p>Paul Gershlick, a Partner and Head of Pharmaceuticals and Life Sciences at Matthew Arnold &amp; Baldwin LLP, welcomed the decision but raised a warning: “This is fantastic news for people with prostate cancer and their families. It is also seemingly good news for the NHS.</p>
<p>“However, at what price? There is much concern in the industry that as costs of bringing new drugs to market are increasing, the price they can charge is falling as pressures are increased on NHS budgets to obtain more for less. In particular, there is concern over the QIPP Agenda, in which the Department of Health has to find billions of savings to obtain better value, and value based pricing &#8211; the new pricing regime about which there is currently not much certainty. If people who invest in research and development in bringing new drugs to market are not sufficiently incentivised to make the profits that ultimately reward their investment and associated risks, we could all suffer in the long-term. It is important that new drugs are valued appropriately to incentivise the new wave of drugs.”</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/abiraterone-drug-nice/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Parliament enquiry report warns of real health risks from delays in medicines</title>
		<link>http://www.mablaw.com/2012/05/appg-medicine-supply-shortage-kevin-barron/</link>
		<comments>http://www.mablaw.com/2012/05/appg-medicine-supply-shortage-kevin-barron/#comments</comments>
		<pubDate>Tue, 15 May 2012 11:16:45 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[International]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[All Party Pharmacy Group]]></category>
		<category><![CDATA[APPG]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[exporter]]></category>
		<category><![CDATA[Kevin Barron]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[medicine supply shortage]]></category>
		<category><![CDATA[medicines]]></category>
		<category><![CDATA[parallel import]]></category>
		<category><![CDATA[parallel importing]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma product]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>
		<category><![CDATA[pharmacy]]></category>
		<category><![CDATA[Wholesale]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19940</guid>
		<description><![CDATA[Patients in England are suffering from dangerous shortages in supplies of medicines and the cause is wholesalers taking advantage of legitimate rights to parallel import the medicines into other countries (such as Germany) where the prices are much more expensive.  Those are the findings of the report of the Parliamentary All Party Pharmacy Group following [...]]]></description>
			<content:encoded><![CDATA[<p>Patients in England are suffering from dangerous shortages in supplies of medicines and the cause is wholesalers taking advantage of legitimate rights to parallel import the medicines into other countries (such as Germany) where the prices are much more expensive.  Those are the findings of the report of the Parliamentary All Party Pharmacy Group following its enquiry into this issue.  It did not blame the suppliers.  Kevin Barron, the MP who chairs the Group, said that suppliers are already manufacturing 20-30% over and above what UK patients need.  &#8220;But sadly UK patients aren&#8217;t getting the drugs in a timely fashion before they&#8217;re sent abroad and that&#8217;s the issue.&#8221;</p>
<p>At any one time, 30-40 medicines are in short supply, and this includes treatments for some cancers, depression and Parkinson&#8217;s disease.  The Group has called on the Government to &#8220;up its game&#8221; and do more to tackle the issue.  The British Association of Pharmaceutical Wholesalers, which represents the nine biggest businesses, supplying 85% of the UK medicines, says that just a few of the 1,700 licence holders are responsible.</p>
<p>The Patients Association has called on the Government to urgently investigate the problem. </p>
<p>The APPG report contemplated whether the Government could consider issuing legal restrictions on the export of medicines on grounds of protecting public health.</p>
<p>Meanwhile, pharmacists have also suffered, as they have had to incur extra costs in sourcing medicines.  The Government has already paid them £12m a year because of that. Some believe that is nowhere near enough to compensate for the problem, and the real issue is for patients.</p>
<p>Amongst the specific recommendations made by the report are:</p>
<ul>
<li>The Government must unequivocally state that the interests of UK patients must come above everything &#8211; not provisions concerned with free movement of goods.</li>
<li>Quota arrangements must be less burdensome for pharmacists and more transparent.</li>
<li>Wholesalers should increase buffer stock.</li>
<li>The Government should consider specific legislation.</li>
<li>Pharmacists should remember the General Pharmaceutical Council&#8217;s guidelines always to put patients first.</li>
<li>There needs to be much better market information.   Market-wide information should be collected and analysed over the next six months.</li>
<li>The Department of Health should update the APPG in six months with details of its progress.</li>
</ul>
<p>Paul Gershlick, a Partner and Head of Pharmaceuticals and Life Sciences at Matthew Arnold &amp; Baldwin LLP, comments: &#8220;It is interesting that this report is looking to address the issue by stopping wholesalers from exporting (except if that does not harm patients).  However, equally, the suppliers could often manufacture more if they want to, but they need to protect their distributors in other countries.  The most important thing is that patients must not be adversely affected and made to suffer when enough medicine could reach them, and I applaud the Group&#8217;s clear message on that.  We are very much looking forward to the seminar we are holding on this important issue on 25 June and to hear what Kevin Barron MP will tell the audience.&#8221;</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/appg-medicine-supply-shortage-kevin-barron/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GPs make mistakes in one in six prescriptions</title>
		<link>http://www.mablaw.com/2012/05/gps-make-mistakes-in-one-in-six-prescriptions/</link>
		<comments>http://www.mablaw.com/2012/05/gps-make-mistakes-in-one-in-six-prescriptions/#comments</comments>
		<pubDate>Tue, 15 May 2012 08:44:17 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[National Health Service]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma product]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical product]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>
		<category><![CDATA[pharmacies]]></category>
		<category><![CDATA[pharmacy]]></category>
		<category><![CDATA[prescription]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19930</guid>
		<description><![CDATA[Doctors are making mistakes in an astonishing one in six prescriptions, according to a General Medical Council study of 1,200 patients. The GMC added that many of the mistakes were thankfully either minor or would have been picked up by the pharmacists before the patients received the drugs. Even so, the figures are too high.  [...]]]></description>
			<content:encoded><![CDATA[<p>Doctors are making mistakes in an astonishing one in six prescriptions, according to a General Medical Council study of 1,200 patients. The GMC added that many of the mistakes were thankfully either minor or would have been picked up by the pharmacists before the patients received the drugs. Even so, the figures are too high.  The mistakes included incomplete information and mistakes over doses and timings. 4% of the mistakes were severe, including patients being prescribed drugs to which they were allergic. Andrew Lansley, the Health Secretary, said the Government was working with GPs to improve the position. He sought to reassure patients that even though there were mistakes, there were systems in place to protect patients and many pharmacists can spot the errors.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/gps-make-mistakes-in-one-in-six-prescriptions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Taxation of vouchers for VAT</title>
		<link>http://www.mablaw.com/2012/05/19932/</link>
		<comments>http://www.mablaw.com/2012/05/19932/#comments</comments>
		<pubDate>Fri, 11 May 2012 15:06:25 +0000</pubDate>
		<dc:creator>Iain Donaldson</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19932</guid>
		<description><![CDATA[There have been a number of changes in the last week to the taxation of vouchers for VAT.  In light of the ECJ decision published on 3 May has caused HMRC to react with some new legislation published which was published yesterday (10 May 2012). We have published some articles on this in www.AccountingWeb.co.uk http://www.accountingweb.co.uk/article/change-law-following-lebara-vat-case/527332 [...]]]></description>
			<content:encoded><![CDATA[<p>There have been a number of changes in the last week to the taxation of vouchers for VAT.  In light of the ECJ decision published on 3 May has caused HMRC to react with some new legislation published which was published yesterday (10 May 2012).</p>
<p>We have published some articles on this in <a href="http://www.accountingweb.co.uk/">www.AccountingWeb.co.uk</a></p>
<p><a href="http://www.accountingweb.co.uk/article/change-law-following-lebara-vat-case/527332">http://www.accountingweb.co.uk/article/change-law-following-lebara-vat-case/527332</a></p>
<p><a href="http://www.accountingweb.co.uk/article/hmrc-loses-lebara-case-phone-card-vat/527167">http://www.accountingweb.co.uk/article/hmrc-loses-lebara-case-phone-card-vat/527167</a></p>
<p>Please note that you may need to register to view the whole article.</p>
<p>This is going to be of interest to two groups:</p>
<ul>
<li>If you sell vouchers as part of your business, you may find that you need to amend the terms of these vouchers or face an unexpected VAT liability.</li>
</ul>
<p> </p>
<ul>
<li>If your business uses third party voucher sellers then you may find that you have been overpaying VAT in light of the HMRC decision and may be able to make a VAT reclaim.</li>
</ul>
<p> </p>
<p>One group who may be affected in particular are issuers and bulk distributers of phonecards.</p>
<p>If this could affect your business please contact Iain Donaldson (<a href="mailto:iain.donaldson@mablaw.com">iain.donaldson@mablaw.com</a>) or Shimon Shaw (<a href="mailto:shimon.shaw@mablaw.com">shimon.shaw@mablaw.com</a>).  For queries in relation to phonecards, please contact Ted Mercer (<a href="mailto:ted.mercer@mablaw.com">ted.mercer@mablaw.com</a>).</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/19932/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Aneurin Bevan Health Board promises to clean up data protection practices after sending mental health patient reports to wrong people</title>
		<link>http://www.mablaw.com/2012/05/aneurin-bevan-health-board-mental-health-repor/</link>
		<comments>http://www.mablaw.com/2012/05/aneurin-bevan-health-board-mental-health-repor/#comments</comments>
		<pubDate>Thu, 10 May 2012 17:27:09 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Data Protection & Privacy (Other Sectors)]]></category>
		<category><![CDATA[Data Providers]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[data breach]]></category>
		<category><![CDATA[data breaches]]></category>
		<category><![CDATA[data controller]]></category>
		<category><![CDATA[data loss]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[data protection act]]></category>
		<category><![CDATA[Data Protection Act 1998]]></category>
		<category><![CDATA[data protection laws]]></category>
		<category><![CDATA[Data Provider]]></category>
		<category><![CDATA[data security]]></category>
		<category><![CDATA[DPA]]></category>
		<category><![CDATA[health board]]></category>
		<category><![CDATA[ICO]]></category>
		<category><![CDATA[Information Commissioner]]></category>
		<category><![CDATA[Information Commissioner's Office]]></category>
		<category><![CDATA[Information Commissioner’s Office]]></category>
		<category><![CDATA[misuse of data]]></category>
		<category><![CDATA[personal data]]></category>
		<category><![CDATA[sensitive personal data]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19911</guid>
		<description><![CDATA[Aneurin Bevan Health Board has signed written undertakings to the Information Commissioner’s Office, promising to clean up its act after carelessly sending detailed psychological reports of mental health patients to the wrong people. The consultant and secretary did not pay close enough attention as to whom the reports should go to and ended up being [...]]]></description>
			<content:encoded><![CDATA[<p>Aneurin Bevan Health Board has signed written undertakings to the Information Commissioner’s Office, promising to clean up its act after carelessly sending detailed psychological reports of mental health patients to the wrong people. The consultant and secretary did not pay close enough attention as to whom the reports should go to and ended up being despatched to people with a similar name. This involved the wrongful sharing of sensitive personal data with people who should not have seen it.  Neither the consultant nor the secretary had received any data protection training.</p>
<p>The ICO has agreed not to issue the Health Board with an enforcement notice, as the Health Board has instead agreed to written undertakings to ensure that all staff including clinical staff are made aware of their data protection policies and receive sufficient training. The Board agreed to take other steps, including processes to confirm patient identity before sending out correspondence.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/aneurin-bevan-health-board-mental-health-repor/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patent cliff takes toll as Pfizer stops marketing world&#8217;s biggest selling drug</title>
		<link>http://www.mablaw.com/2012/05/patent-cliff-pfizer-lipitor-2/</link>
		<comments>http://www.mablaw.com/2012/05/patent-cliff-pfizer-lipitor-2/#comments</comments>
		<pubDate>Thu, 10 May 2012 17:26:30 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[Inventions]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[big pharma]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[innovate]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Intellectual property]]></category>
		<category><![CDATA[intellectual property rights]]></category>
		<category><![CDATA[invention]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[patent]]></category>
		<category><![CDATA[patent cliff]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma product]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical patent]]></category>
		<category><![CDATA[pharmaceutical patents]]></category>
		<category><![CDATA[pharmaceutical product]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19923</guid>
		<description><![CDATA[Pfizer has announced that it is stopping marketing its Lipitor product. The cholesterol-lowering drug is the biggest selling drug in the world. But Pfizer is suffering after Lipitor&#8217;s patent expired a few months ago. It is now really feeling the effects of generic competition. Lipitor once accounted for a quarter of Pfizer&#8217;s revenue but it has now [...]]]></description>
			<content:encoded><![CDATA[<p>Pfizer has announced that it is stopping marketing its Lipitor product. The cholesterol-lowering drug is the biggest selling drug in the world. But Pfizer is suffering after Lipitor&#8217;s patent expired a few months ago. It is now really feeling the effects of generic competition. Lipitor once accounted for a quarter of Pfizer&#8217;s revenue but it has now turned its back on the drug altogether.</p>
<p>Paul Gershlick, a Partner and Head of Pharmaceuticals and Life Sciences at Matthew Arnold &amp; Baldwin LLP, comments: &#8220;These are the dramatic effects being felt in just one drug falling out of patent during the so-called patent cliff.  The patent cliff is the period between 2011 and 2016 when many of big pharma&#8217;s blockbuster drugs fall out of patent without sufficient replacements in the pipeline to make up the revenue shortfall. This period is going to re-shape the whole pharmaceutical industry. It is a time of threat to big pharma companies but also a time of opportunity for new business models.&#8221;</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/patent-cliff-pfizer-lipitor-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Squatting in a residential property has become a criminal offence</title>
		<link>http://www.mablaw.com/2012/05/squatting-in-a-residential-property-has-become-a-criminal-offence-legal-aid-sentencing-and-punishment-of-offenders-act-2012/</link>
		<comments>http://www.mablaw.com/2012/05/squatting-in-a-residential-property-has-become-a-criminal-offence-legal-aid-sentencing-and-punishment-of-offenders-act-2012/#comments</comments>
		<pubDate>Thu, 10 May 2012 16:19:50 +0000</pubDate>
		<dc:creator>Richard John</dc:creator>
				<category><![CDATA[Commercial Developers]]></category>
		<category><![CDATA[Commercial Development]]></category>
		<category><![CDATA[Commercial Property]]></category>
		<category><![CDATA[Landlord & Tenant]]></category>
		<category><![CDATA[Landlords]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Plot Sales]]></category>
		<category><![CDATA[Residential Developers]]></category>
		<category><![CDATA[Upload-RealEstate]]></category>
		<category><![CDATA[criminal]]></category>
		<category><![CDATA[Legal Aid Sentencing and Punishment of Offenders Bill]]></category>
		<category><![CDATA[residential property]]></category>
		<category><![CDATA[squatters]]></category>
		<category><![CDATA[squatting]]></category>
		<category><![CDATA[trespass]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19919</guid>
		<description><![CDATA[The Legal Aid, Sentencing and Punishment of Offenders Act 2012 received Royal Assent on 1 May 2012. This is good news for residential property owners. Section 144 of the Act creates a new criminal offence of squatting in a residential building. Under the Act, a squatting offence will be deemed to have been committed if [...]]]></description>
			<content:encoded><![CDATA[<p>The <em>Legal Aid, Sentencing and Punishment of Offenders Act 2012</em> received Royal Assent on 1 May 2012.</p>
<p>This is good news for residential property owners.</p>
<p>Section 144 of the Act creates a new criminal offence of squatting in a residential building. Under the Act, a squatting offence will be deemed to have been committed if a person does all of the following:</p>
<p>1. Is in a residential building as a trespasser, having entered it as a trespasser;</p>
<p>2. Knows or ought to know that he or she is a trespasser; and</p>
<p>3. Is living in the building or intends to live there for any period of time</p>
<p>Although section 144 has not yet come into force (and no definite date has been given at the time of writing), if a person enters a residential building as a trespasser before or after the section’s enforcement, that person will have committed an offence under the Act. Offenders face up to one year in prison and/or a fine of up to £5000.  Some further background information is <a href="http://www.mablaw.com/2011/11/squatting-in-residential-properties-is-set-to-become-a-criminal-offence/">here</a>.</p>
<p>There are a number of exceptions to this new offence, where an offence will not have been committed &#8211; for example, when a legitimate tenant or occupier who has occupied a property with permission refuses to leave following a disagreement with the landlord.</p>
<p>Importantly, the Act does not extend to commercial properties, so commercial property owners will have to continue to evict squatters through the civil possession procedure.</p>
<p>The Act is expected to come into force in September 2012, but we are awaiting confirmation.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/squatting-in-a-residential-property-has-become-a-criminal-offence-legal-aid-sentencing-and-punishment-of-offenders-act-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Threat to pharma sector innovation as University of York recommends lowering of top threshold for drug costs</title>
		<link>http://www.mablaw.com/2012/05/pharma-sector-university-york/</link>
		<comments>http://www.mablaw.com/2012/05/pharma-sector-university-york/#comments</comments>
		<pubDate>Wed, 09 May 2012 17:26:07 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Inventions]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[National Institute for Health and Clinical Excellence]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma product]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical product]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>
		<category><![CDATA[QALY]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19925</guid>
		<description><![CDATA[At a time when innovative pharma sector companies are facing the squeeze with pressure on pricing and high costs of bringing new products to market, they have now received further bad news. The University of York has called for the notional cap on the cost of drugs used by the National Institute for Health and Clinical [...]]]></description>
			<content:encoded><![CDATA[<p>At a time when innovative pharma sector companies are facing the squeeze with pressure on pricing and high costs of bringing new products to market, they have now received further bad news. The University of York has called for the notional cap on the cost of drugs used by the National Institute for Health and Clinical Excellence (NICE) to be reduced by one-third or even two-thirds when deciding on which drugs to fund. The University is funded by the Medical Research Council and work closely with NICE and the Department of Health, so its recommendations are likely to hold weight.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/pharma-sector-university-york/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GSK says it will not make a move for AZ as big pharma struggles to cope with patent cliff</title>
		<link>http://www.mablaw.com/2012/05/gsk-says-it-will-not-make-a-move-for-az-as-big-pharma-struggles-to-cope-with-patent-cliff/</link>
		<comments>http://www.mablaw.com/2012/05/gsk-says-it-will-not-make-a-move-for-az-as-big-pharma-struggles-to-cope-with-patent-cliff/#comments</comments>
		<pubDate>Mon, 07 May 2012 20:22:18 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[Inventions]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[big pharma]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[innovate]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual property]]></category>
		<category><![CDATA[intellectual property rights]]></category>
		<category><![CDATA[invent]]></category>
		<category><![CDATA[invention]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[patent]]></category>
		<category><![CDATA[patent cliff]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma product]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical patent]]></category>
		<category><![CDATA[pharmaceutical patents]]></category>
		<category><![CDATA[pharmaceutical product]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19908</guid>
		<description><![CDATA[GSK, the biggest UK pharmaceuticals company, has ruled out a bid for the second biggest AstraZeneca. The GSK chief executive, Andrew Witty, said that such a move would be distracting. He believes that GSK&#8217;s pipeline new drugs are entering an exciting time. Meanwhile, AZ&#8217;s chief executive, David Brennan, is retiring on 1 June  as the big pharma [...]]]></description>
			<content:encoded><![CDATA[<p>GSK, the biggest UK pharmaceuticals company, has ruled out a bid for the second biggest AstraZeneca. The GSK chief executive, Andrew Witty, said that such a move would be distracting. He believes that GSK&#8217;s pipeline new drugs are entering an exciting time.</p>
<p>Meanwhile, AZ&#8217;s chief executive, David Brennan, is retiring on 1 June  as the big pharma company battles to maintain revenues after losing out to generics competitors. Brennan said that the pharma sector was “experiencing pressures none of which I’ve witnessed in my 36 years in the industry&#8221;. Like many big pharma companies, AZ is feeling the effects of the patent cliff, which is the falling out of patent of many of their blockbuster drugs between 2011 and 2016 without sufficient replacements coming through.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/gsk-says-it-will-not-make-a-move-for-az-as-big-pharma-struggles-to-cope-with-patent-cliff/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patent cliff damage shown in Pfizer&#8217;s results after Lipitor lost revenues</title>
		<link>http://www.mablaw.com/2012/05/patent-cliff-pfizer-lipitor/</link>
		<comments>http://www.mablaw.com/2012/05/patent-cliff-pfizer-lipitor/#comments</comments>
		<pubDate>Mon, 07 May 2012 18:29:18 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[Inventions]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[big pharma]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Intellectual property]]></category>
		<category><![CDATA[intellectual property rights]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[patent]]></category>
		<category><![CDATA[patent cliff]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical patent]]></category>
		<category><![CDATA[pharmaceutical patents]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19905</guid>
		<description><![CDATA[Pfizer has suffered a big dent in both its revenues and earnings as it has felt the fall brunt of its Lipitor cholesterol blockbuster drug coming off patent.  In the first quarter this year, the pharmaceutical giant&#8217;s revenues fell 7% and its earnings by 19% after its Lipitor sales figures fell by 42% to US$1.4bn. [...]]]></description>
			<content:encoded><![CDATA[<p>Pfizer has suffered a big dent in both its revenues and earnings as it has felt the fall brunt of its Lipitor cholesterol blockbuster drug coming off patent.  In the first quarter this year, the pharmaceutical giant&#8217;s revenues fell 7% and its earnings by 19% after its Lipitor sales figures fell by 42% to US$1.4bn. The patent rights for Lipitor expired a few months ago, leading to competition from generics companies. </p>
<p>Lipitor is one of the first drugs to come off patent in what is coined the &#8220;patent cliff&#8221;. The patent cliff refers to the falling out of patent of a large number of blockbuster drugs between 2011 and 2016 without sufficient replacements coming through in the pipeline. </p>
<p>Paul Gershlick, a Partner and Head of Pharmaceuticals and Life Sciences at Matthew Arnold &amp; Baldwin LLP, comments: &#8220;Many experts see the patent cliff as heralding a new era in the pharmaceutical sector as big pharma companies will struggle to cope with the massive loss of revenues that they will suffer. How they and others in the sector adapt to the new position will determine who will survive, who will thrive and who will not make it.&#8221;</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/patent-cliff-pfizer-lipitor/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Department of Health agrees to survey pharmacists to address medicine shortage crisis</title>
		<link>http://www.mablaw.com/2012/05/department-health-pharmacist-medicine-shortage/</link>
		<comments>http://www.mablaw.com/2012/05/department-health-pharmacist-medicine-shortage/#comments</comments>
		<pubDate>Fri, 04 May 2012 17:30:14 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[medicine supply shortage]]></category>
		<category><![CDATA[medicines]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>
		<category><![CDATA[pharmacies]]></category>
		<category><![CDATA[pharmacy]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19894</guid>
		<description><![CDATA[The Department of Health has agreed to consider surveying community pharmacies to find out the impact of medicine supply shortages. The situation is so important that the All Party Pharmacy Group has held an enquiry on it, although the Government has not responded to the issue. Recently, a Chemist and Drugist survey has found that more [...]]]></description>
			<content:encoded><![CDATA[<p>The Department of Health has agreed to consider surveying community pharmacies to find out the impact of medicine supply shortages. The situation is so important that the All Party Pharmacy Group has held an enquiry on it, although the Government has not responded to the issue. Recently, a <em>Chemist and Drugist </em>survey has found that more than 140 pharmacists had seen a patient&#8217;s health suffer as a result of the medicine supply shortage. MP Huw Irranca-Davies, who has been pressing the issue, has been trying to keep the issue up on the Government&#8217;s agenda and has hailed this decision as a vital breakthrough. He has urged pharmacists to write to their MPs to keep the pressure on the Government to undertake the survey.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/department-health-pharmacist-medicine-shortage/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Independent Pharmacy Federation calls for 100 MPs to back an early day motion on drugs shortage crisis</title>
		<link>http://www.mablaw.com/2012/05/independent-pharmacy-federation-medicine-supply-shortage/</link>
		<comments>http://www.mablaw.com/2012/05/independent-pharmacy-federation-medicine-supply-shortage/#comments</comments>
		<pubDate>Fri, 04 May 2012 17:19:06 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[International]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Wholesalers]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[exporter]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[medicine supply shortage]]></category>
		<category><![CDATA[medicines]]></category>
		<category><![CDATA[parallel import]]></category>
		<category><![CDATA[parallel importing]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>
		<category><![CDATA[pharmacies]]></category>
		<category><![CDATA[pharmacy]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19879</guid>
		<description><![CDATA[The Independent Pharmacy Federation, which represents many independent pharmacists in the UK, has called for at least 100 MPs to back a Parliamentary early day motion tabled by Keith Vaz MP to address the medicine supply shortage issue. The IPF has prepared a letter to go to MPs on behalf of its pharmacy members. The IPF [...]]]></description>
			<content:encoded><![CDATA[<p>The Independent Pharmacy Federation, which represents many independent pharmacists in the UK, has called for at least 100 MPs to back a Parliamentary early day motion tabled by Keith Vaz MP to address the medicine supply shortage issue. The IPF has prepared a letter to go to MPs on behalf of its pharmacy members. The IPF is looking for minimum supply standards.</p>
<p>Claire Ward, CEO of the IPF, says, &#8220;It is unacceptable that patients’ health and lives are being put at risk by this failure in the supply chain. Pharmacists are sometimes wrongly getting the blame when the fault lies in other places.”</p>
<p>Paul Gershlick, a Partner and Head of Pharmaceuticals and Life Sciences at Matthew Arnold &amp; Baldwin LLP, says: &#8220;This is a massive issue. It needs sorting. Anything that Parliament can do to address it is crucial. People&#8217;s lives are being put at risk, with at least one reported death arising out of the supply chain problems. Whether the issue is with too many drugs being exported to take advantage of commercial opportunities arising out of differential prices in different countries, or suppliers withholding supplies so that they can sell more in other countries at a higher rate, a solution is needed to protect patients&#8217; interests. The All Party Pharmacy Group at Parliament has recently held an enquiry into the issue, and we look forward to their findings in June.&#8221;</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/independent-pharmacy-federation-medicine-supply-shortage/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GSK accuses NICE of failure to support new drugs</title>
		<link>http://www.mablaw.com/2012/05/gsk-nice-support-new-drugs/</link>
		<comments>http://www.mablaw.com/2012/05/gsk-nice-support-new-drugs/#comments</comments>
		<pubDate>Fri, 04 May 2012 17:18:45 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[Inventions]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Assoication of the British Pharmaceutical Industry]]></category>
		<category><![CDATA[big pharma]]></category>
		<category><![CDATA[innovate]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[National Institute for Health and Clinical Excellence]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19890</guid>
		<description><![CDATA[GSK, the UK&#8217;s largest pharmaceutical company, has accused the National Institute for Health and Clinical Excellence (NICE) of failing to do enough to recognise the value of new medicines and encourage innovation in the pharmaceutical sector. GSK&#8217;s voiced its concerns after its Benlysta belimumab product was not approved for the treatment of lupus.  Lupus is [...]]]></description>
			<content:encoded><![CDATA[<p>GSK, the UK&#8217;s largest pharmaceutical company, has accused the National Institute for Health and Clinical Excellence (NICE) of failing to do enough to recognise the value of new medicines and encourage innovation in the pharmaceutical sector. GSK&#8217;s voiced its concerns after its Benlysta belimumab product was not approved for the treatment of lupus.  Lupus is an incurable autoimmune condition where the immune system attacks healthy tissue instead of fighting disease, damaging organs such as the heart and kidneys.</p>
<p>GSK said that the system for approving new drugs had to change.  It said: &#8220; &#8221;The failure to recognise and adopt innovative new medicines continues to be a systemic problem in the UK … The UK is a world leader in the research, development and manufacture of medicines, but is one of the slowest to enable patients to have access to innovative new treatments. This is a situation that must be addressed.&#8221;</p>
<p>In response, NICE has said that it had to recognise how new products added to the existing care already available, and if they cost a lot and did not add much in terms of improvement, that would affect whether they would be promoted. NICE had consulted with patients and doctors and concluded that the cost did not justify the relative improvements made compared to current standard care available.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/gsk-nice-support-new-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ECJ rules that infringements claims based on keywords can be heard by courts in country where advertiser established – Wintersteiger AG v Products 4U, European Court of Justice</title>
		<link>http://www.mablaw.com/2012/05/ecj-trade-mark-keywords-jurisdiction/</link>
		<comments>http://www.mablaw.com/2012/05/ecj-trade-mark-keywords-jurisdiction/#comments</comments>
		<pubDate>Fri, 04 May 2012 17:04:19 +0000</pubDate>
		<dc:creator>Simon Weinberg</dc:creator>
				<category><![CDATA[Brands]]></category>
		<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Online]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[Websites]]></category>
		<category><![CDATA[advertiser]]></category>
		<category><![CDATA[adverts]]></category>
		<category><![CDATA[advocate general]]></category>
		<category><![CDATA[adword]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[ECJ]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[European Commission]]></category>
		<category><![CDATA[European Court of Justice]]></category>
		<category><![CDATA[European Union]]></category>
		<category><![CDATA[Google]]></category>
		<category><![CDATA[illegal]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[Intellectual property]]></category>
		<category><![CDATA[intellectual property rights]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[jurisdiction]]></category>
		<category><![CDATA[keyword]]></category>
		<category><![CDATA[Member State]]></category>
		<category><![CDATA[online content]]></category>
		<category><![CDATA[Products 4U]]></category>
		<category><![CDATA[trade mark]]></category>
		<category><![CDATA[trade mark infringement]]></category>
		<category><![CDATA[trade marks]]></category>
		<category><![CDATA[unauthorised]]></category>
		<category><![CDATA[unlawful]]></category>
		<category><![CDATA[web]]></category>
		<category><![CDATA[web site]]></category>
		<category><![CDATA[web sites]]></category>
		<category><![CDATA[Website]]></category>
		<category><![CDATA[website content]]></category>
		<category><![CDATA[websites]]></category>
		<category><![CDATA[Wintersteiger]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19873</guid>
		<description><![CDATA[The European Court of Justice (ECJ) has ruled that, where an action is brought for trade mark infringement by using, for example, Google’s “adwords”, that action can be heard by the courts in the member state both where the infringed trade mark is registered and where the advertiser is “established”. In this instance, Wintersteiger, an [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://curia.europa.eu/juris/document/document.jsf?text=&amp;docid=121744&amp;pageIndex=0&amp;doclang=en&amp;mode=req&amp;dir=&amp;occ=first&amp;part=1&amp;cid=1147102">The European Court of Justice (ECJ) has ruled that, where an action is brought for trade mark infringement by using, for example, Google’s “adwords”, that action can be heard by the courts in the member state both where the infringed trade mark is registered and where the advertiser is “established”</a>.</p>
<p>In this instance, Wintersteiger, an Austrian business, accused its German competitor, Products 4U, of registering the adword “Wintersteiger” so that, when a consumer searched for “Wintersteiger” on google.de, the Product 4U website came up. Wintersteiger issued proceedings for trade mark infringement in the Austrian courts, as it had registered the word mark “Wintersteiger” in Austria. The Austrian courts had initially rejected the application on the grounds that it did not have jurisdiction as the issue related to google.de and not google.at.</p>
<p>Advocate General Cruz Villalón, an advisor to the ECJ, had advised that proceedings could be brought (i) in the country where the infringed trade mark was registered (in this case, Austria), or (ii) in the country corresponding to the country code in the relevant search engine’s top level domain name (in this case Germany).</p>
<p>However, the Advocate General’s views are not binding, and the ECJ ruled in a slightly more restrictive way in relation to (ii) above; that such claims can only be brought in that member state if the alleged infringing advertiser has an “establishment” there. It is not clear what “establishment” means, and whether it means anything different from “domiciled”, as the ECJ didn’t give an opinion on that specific point; future cases on this will hopefully clarify that issue.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/ecj-trade-mark-keywords-jurisdiction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ABPI launches new partnership team to work closer with providing greater access to innovative treatments to NHS patients</title>
		<link>http://www.mablaw.com/2012/05/abpi-nhs-innovation-partnership/</link>
		<comments>http://www.mablaw.com/2012/05/abpi-nhs-innovation-partnership/#comments</comments>
		<pubDate>Fri, 04 May 2012 16:59:43 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Inventions]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[ABPI]]></category>
		<category><![CDATA[Assoication of the British Pharmaceutical Industry]]></category>
		<category><![CDATA[big pharma]]></category>
		<category><![CDATA[innovate]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Innovation Health and Wealth]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[National Health Service]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[Partnership]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19886</guid>
		<description><![CDATA[The Association of the British Pharmaceutical Industry has announced a new regional team to work closer with the NHS to bring innovative treatments quicker to NHS patients. The ABPI is delighted about the Government&#8217;s plans to work closer with the pharma industry, as demonstrated in the Government’s Innovation Health and Wealth report, which looked to [...]]]></description>
			<content:encoded><![CDATA[<p>The Association of the British Pharmaceutical Industry has announced a new regional team to work closer with the NHS to bring innovative treatments quicker to NHS patients. The ABPI is delighted about the Government&#8217;s plans to work closer with the pharma industry, as demonstrated in the Government’s <em>Innovation Health and Wealth</em> report, which looked to encourage the quicker adoption of innovative medicines.</p>
<p>Stephen Whitehead, the CEO of the ABPI, said: &#8220;I firmly believe partnership working is the future of healthcare in the UK. Generic medicines do save us money, but it is innovation that saves lives. We have to be careful not to focus on cost saving when we should be focusing on patients. &#8221;</p>
<p>He highlighted the fact that developing new innovative medicines could save money elsewhere in care, such as with Alzheimer&#8217;s. He warned about the understandable concern for the NHS to keep prices down, as any failure to recognise and value innovation would mean lives would suffer. He saw the partnership opportunities as enabling the NHS and industry to work together for the good of improving healthcare.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/abpi-nhs-innovation-partnership/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Details of staff members who dealt with complaints could be released under freedom of information request as they were not within the sphere of privacy to be personal data</title>
		<link>http://www.mablaw.com/2012/05/staff-members-fsa-personal-data-privacy-biographical/</link>
		<comments>http://www.mablaw.com/2012/05/staff-members-fsa-personal-data-privacy-biographical/#comments</comments>
		<pubDate>Fri, 04 May 2012 16:43:59 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Data Protection & Privacy (Other Sectors)]]></category>
		<category><![CDATA[Data Providers]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[biographical]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[data controller]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[data protection act]]></category>
		<category><![CDATA[Data Protection Act 1998]]></category>
		<category><![CDATA[data protection laws]]></category>
		<category><![CDATA[Data Provider]]></category>
		<category><![CDATA[DPA]]></category>
		<category><![CDATA[FOIA]]></category>
		<category><![CDATA[freedom of information]]></category>
		<category><![CDATA[freedom of information act]]></category>
		<category><![CDATA[freedom of information request]]></category>
		<category><![CDATA[ICO]]></category>
		<category><![CDATA[information]]></category>
		<category><![CDATA[Information Commissioner]]></category>
		<category><![CDATA[Information Commissioner's Office]]></category>
		<category><![CDATA[Information Tribunal]]></category>
		<category><![CDATA[personal data]]></category>
		<category><![CDATA[privacy]]></category>
		<category><![CDATA[request for information]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19865</guid>
		<description><![CDATA[Mr Edem had made a freedom of information request to the Financial Services Authority for information relating to a complaint he had made about Egg. He was concerned that the FSA had failed to regulate Egg properly. The FSA refused to supply the names of staff who had dealt with his complaint on the grounds [...]]]></description>
			<content:encoded><![CDATA[<p>Mr Edem had made a freedom of information request to the Financial Services Authority for information relating to a complaint he had made about Egg. He was concerned that the FSA had failed to regulate Egg properly. The FSA refused to supply the names of staff who had dealt with his complaint on the grounds that they constituted personal data and were therefore exempt from disclosure under the Freedom of Information Act.</p>
<p>The Information Commissioner’s Office had agreed with the FSA’s decision, but now the Information Rights Tribunal has ruled that the names should not have been withheld as they did not amount to “personal data”. To be “personal data” under the Data Protection Act, the data needed to be biographical to affect the people’s privacy. Just providing the name was not something so as to affect their privacy. That might have been different, however, if the nature of the people’s involvement gave away other information about them and their views, such as if they worked for an organisation that conducted experiments on animals. That was not the case here, though.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/staff-members-fsa-personal-data-privacy-biographical/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Asda refused permission to appeal to Supreme Court in Specsavers case &#8211; Specsavers International Healthcare Limited v Asda Stores Limited, Court of Appeal</title>
		<link>http://www.mablaw.com/2012/05/asda-specsavers-trade-mark-infringement-injunction-appeal/</link>
		<comments>http://www.mablaw.com/2012/05/asda-specsavers-trade-mark-infringement-injunction-appeal/#comments</comments>
		<pubDate>Fri, 04 May 2012 16:43:39 +0000</pubDate>
		<dc:creator>Simon Weinberg</dc:creator>
				<category><![CDATA[Brands]]></category>
		<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[advertising]]></category>
		<category><![CDATA[advertising campaign]]></category>
		<category><![CDATA[adverts]]></category>
		<category><![CDATA[Asda]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Community Trade Marks Regulation]]></category>
		<category><![CDATA[confusion]]></category>
		<category><![CDATA[Court of Appeal]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[injunction]]></category>
		<category><![CDATA[Intellectual property]]></category>
		<category><![CDATA[intellectual property rights]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[logo]]></category>
		<category><![CDATA[reasonable consumer]]></category>
		<category><![CDATA[rebranding]]></category>
		<category><![CDATA[Specsavers]]></category>
		<category><![CDATA[straplines]]></category>
		<category><![CDATA[trade mark]]></category>
		<category><![CDATA[trade marks]]></category>
		<category><![CDATA[unfair advantage]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19876</guid>
		<description><![CDATA[The Court of Appeal recently ruled that Asda had infringed some of Specsavers’ registered trade marks in an advertising campaign by using certain straplines and a logo on the grounds of unfair advantage under article 9(1)(c) of the Community Trade Marks Regulation. The Court of Appeal had rejected the claims that Asda had also infringed [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.mablaw.com/2012/02/specsavers-appeals-against-asda-upheld/">The Court of Appeal recently ruled that Asda had infringed some of Specsavers’ registered trade marks in an advertising campaign by using certain straplines and a logo on the grounds of unfair advantage under article 9(1)(c) of the Community Trade Marks Regulation. The Court of Appeal had rejected the claims that Asda had also infringed article 9(1)(b) of that Regulation by confusing consumers.</a></p>
<p><a href="http://www.bailii.org/cgi-bin/markup.cgi?doc=/ew/cases/EWCA/Civ/2012/494.html&amp;query=asda&amp;method=boolean">The Court of Appeal has now ruled</a> on the terms of an injunction to ensure that no further infringement takes place, and has rejected Asda’s application for permission to appeal the decision to the Supreme Court. Specsavers and Asda had agreed that the injunction should prevent Asda from using the straplines “be a real spec saver at Asda” and “spec saving at Asda” as well as the logo comprising two adjacent ellipses, which were the subject of the successful claim by Specsavers under article 9(1)(c). However, Specsavers wanted the injunction to cover similar uses of the straplines and logo as well, whereas Asda said that more general wording was not needed as it had stopped using the straplines and the logo in any case.</p>
<p>The Court of Appeal ruled that, because:</p>
<p>(i)           Specsavers and Asda were still competitors and Asda’s original campaign specifically targeted Specsavers’ customers; and</p>
<p>(ii)          Asda had not given any undertaking as to its future conduct;</p>
<p>a general form of injunction, as applied for by Specsavers, was appropriate. This was to ensure, for example, that Asda did not use straplines that were merely a slight variation from those that the Court of Appeal’s had originally ruled infringed Specsavers’ trade marks.</p>
<p>In addition, the Court of Appeal rejected Asda’s application for leave to appeal to the Supreme Court. Asda’s argument was that the injunction was not justified by the infringement that had taken place, but the Court of Appeal rejected that argument.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/asda-specsavers-trade-mark-infringement-injunction-appeal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TripAdvisor latest to complain about Google’s alleged abuse of dominant position in placement of competing sites in search results</title>
		<link>http://www.mablaw.com/2012/05/tripadvisor-google-abuse-dominant-position/</link>
		<comments>http://www.mablaw.com/2012/05/tripadvisor-google-abuse-dominant-position/#comments</comments>
		<pubDate>Fri, 04 May 2012 16:39:42 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Online]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[Websites]]></category>
		<category><![CDATA[abuse]]></category>
		<category><![CDATA[abuse of dominance]]></category>
		<category><![CDATA[abuse of dominant position]]></category>
		<category><![CDATA[anti-competition]]></category>
		<category><![CDATA[anti-competitive]]></category>
		<category><![CDATA[breach of competition law]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[competition law]]></category>
		<category><![CDATA[dominance]]></category>
		<category><![CDATA[dominant position]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[EU law]]></category>
		<category><![CDATA[EU laws]]></category>
		<category><![CDATA[European Commission]]></category>
		<category><![CDATA[European Union]]></category>
		<category><![CDATA[fine]]></category>
		<category><![CDATA[illegal]]></category>
		<category><![CDATA[On-line]]></category>
		<category><![CDATA[online content]]></category>
		<category><![CDATA[search]]></category>
		<category><![CDATA[search engine]]></category>
		<category><![CDATA[search engines]]></category>
		<category><![CDATA[search result]]></category>
		<category><![CDATA[unenforceable]]></category>
		<category><![CDATA[web]]></category>
		<category><![CDATA[web site]]></category>
		<category><![CDATA[web site content]]></category>
		<category><![CDATA[web sites]]></category>
		<category><![CDATA[Website]]></category>
		<category><![CDATA[website content]]></category>
		<category><![CDATA[websites]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19863</guid>
		<description><![CDATA[TripAdvisor has become the latest business to complain that Google has allegedly abused its dominant position in the way it displays search results. TripAdvisor alleges that the search engine giant puts its own travel review site ahead of its competitors. In so doing, it is using its dominance in the search market to take advantage [...]]]></description>
			<content:encoded><![CDATA[<p>TripAdvisor has become the latest business to complain that Google has allegedly abused its dominant position in the way it displays search results. TripAdvisor alleges that the search engine giant puts its own travel review site ahead of its competitors. In so doing, it is using its dominance in the search market to take advantage of other competing businesses for Google’s other services. Expedia has already made a similar complaint about Google to the European Commission. Meanwhile, other sites including Microsoft’s Ciao price comparison site have said similar things.  Microsoft has also alleged that its Bing search engine has found it playing on an uneven playing field when it wanted to link to Google’s YouTube.</p>
<p>The European Commission is already looking into whether Google is abusing its dominant position in the way in which it lists competitors’ sites. If found guilty of breaching European Union competition law, Google could face very tough sanctions including a fine of up to 10% of its turnover. No doubt, the slow wheels of this case will run and run for many months yet.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/tripadvisor-google-abuse-dominant-position/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Web site operator may be liable for site to which it links – McGrath v Dawkins, High Court</title>
		<link>http://www.mablaw.com/2012/05/web-site-operator-liability-hyperlink-mcgrath-dawkins/</link>
		<comments>http://www.mablaw.com/2012/05/web-site-operator-liability-hyperlink-mcgrath-dawkins/#comments</comments>
		<pubDate>Fri, 04 May 2012 16:39:13 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Online]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[Websites]]></category>
		<category><![CDATA[e-commerce]]></category>
		<category><![CDATA[E-Commerce Directive]]></category>
		<category><![CDATA[E-Commerce Regulations]]></category>
		<category><![CDATA[High Court]]></category>
		<category><![CDATA[hyperlink]]></category>
		<category><![CDATA[liability]]></category>
		<category><![CDATA[liable]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[links]]></category>
		<category><![CDATA[On-line]]></category>
		<category><![CDATA[online content]]></category>
		<category><![CDATA[web]]></category>
		<category><![CDATA[web site]]></category>
		<category><![CDATA[web site content]]></category>
		<category><![CDATA[web sites]]></category>
		<category><![CDATA[Website]]></category>
		<category><![CDATA[website content]]></category>
		<category><![CDATA[websites]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19861</guid>
		<description><![CDATA[McGrath sued Professor Richard Dawkins and various others for allegedly defamatory material posted on a web site. This was an application by the defendants to strike out the claim. The most interesting aspect of this action was that The Richard Dawkins Foundation, which operated the richarddawkinsfoundation.org web site, was potentially liable for another web site [...]]]></description>
			<content:encoded><![CDATA[<p>McGrath sued Professor Richard Dawkins and various others for allegedly defamatory material posted on a web site. This was an application by the defendants to strike out the claim. The most interesting aspect of this action was that The Richard Dawkins Foundation, which operated the richarddawkinsfoundation.org web site, was potentially liable for another web site to which that site linked. When someone went to the home page of the .org web site, they linked straight through to the richarddawkins.net site. The Foundation did not operate the .net site, but the High Court ruled that the fact that there was a link through to that other site meant that the Foundation could still be liable even though the .org web site itself did not have any defamatory postings.</p>
<p> It was a question of fact on a case by case basis as to whether the linking site was liable. In this case, the two web sites seemed to be closely associated and the home page of the .org site went through to the .net site. Although this ruling does not mean that the Foundation was liable, the Court refused to grant the strike out application and said it should be decided at trial as the result was not sufficiently certain.</p>
<p>We now await the main court case to find out more about liability for sites that provide a link.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/web-site-operator-liability-hyperlink-mcgrath-dawkins/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>High Court rules that duty of good faith was breached by acting arbitrarily, capriciously and irrationally – Compass Group UK and Ireland Ltd (trading as Medirest) v Mid Essex Hospital Services NHS Trust, High Court</title>
		<link>http://www.mablaw.com/2012/05/high-court-good-faith-breach-medirest-nhs/</link>
		<comments>http://www.mablaw.com/2012/05/high-court-good-faith-breach-medirest-nhs/#comments</comments>
		<pubDate>Thu, 03 May 2012 20:41:33 +0000</pubDate>
		<dc:creator>Simon Weinberg</dc:creator>
				<category><![CDATA[Commercial Contracts]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[catering]]></category>
		<category><![CDATA[commercial agreement]]></category>
		<category><![CDATA[Commercial contract]]></category>
		<category><![CDATA[commercial contracts]]></category>
		<category><![CDATA[contract]]></category>
		<category><![CDATA[contract law]]></category>
		<category><![CDATA[contracts]]></category>
		<category><![CDATA[duty of good faith]]></category>
		<category><![CDATA[High Court]]></category>
		<category><![CDATA[Medirest]]></category>
		<category><![CDATA[National Health Service]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[outsource]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[outsourcing agreement]]></category>
		<category><![CDATA[service credits]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19817</guid>
		<description><![CDATA[Medirest entered into an agreement with Mid Essex Hospital Services NHS Trust (the Trust) for the supply of catering services in a hospital. The agreement contained a clause that obliged the parties to:   “co-operate with each other in good faith and… take all reasonable action as is necessary for the efficient transmission of information [...]]]></description>
			<content:encoded><![CDATA[<p>Medirest entered into an agreement with Mid Essex Hospital Services NHS Trust (the Trust) for the supply of catering services in a hospital. The agreement contained a clause that obliged the parties to:</p>
<p><strong> </strong></p>
<p>“co-operate with each other in good faith and… take all reasonable action as is necessary for the efficient transmission of information and instructions and to enable the Trust… to derive the full benefit of the Contract.&#8221;</p>
<p>Medirest argued that the clause should be interpreted widely – that it included a general obligation to co-operate in good faith, and a restricted obligation to take reasonably necessary action to transfer information and allow for full benefit from the agreement. The Trust argued with this interpretation, and said that both obligations were restricted to the transfer of information and to allow for the full benefit of the agreement, so there was no general duty to co-operate in good faith.</p>
<p>The agreement contained a provision that allowed for service credits (a reduction in fees payable to Medirest) if Medirest failed to perform any of its obligations under the agreement, and the Trust could terminate if service credits reached a certain level. On the flip side, Medirest could terminate the agreement if the Trust committed a material breach. The Trust argued that it was entitled to service credits, and Medirest disagreed, resulting in each party serving the other with notice of termination of the agreement.</p>
<p><a href="http://www.bailii.org/ew/cases/EWHC/QB/2012/781.html">The High Court ruled</a> that the clause set out above did contain a general contractual duty to act in good faith. The High Court noted that the services to be provided were catering services within a hospital, so on-going co-operation was an inevitable part of the contractual relationship; it interpreted the clause as it understood the parties’ intentions to be when entering into the contract – to co-operate in good faith.</p>
<p>The High Court went on to say that the Trust had abused its contractual powers in relation to service credits. The High Court said that the purpose of service credits was to make sure performance was at a consistently good level, but not to get discounts in the fees payable to Medirest, and the Trust’s calculations of service credits often went beyond what was reasonable. The Trust acted arbitrarily, capriciously and irrationally in the way in which it carried out the credits.</p>
<p>The result was that Medirest were entitled to terminate the agreement as the excessive service credit calculations were material breaches of the agreement. In fact, Medirest argued that the Trust’s breaches were repudiatory i.e. the breaches were sufficiently serious to go to the heart of the ability to carry on the contract and allow Medirest to treat the agreement as terminated with immediate effect, and giving Medirest the right to sue the Trust for damages.</p>
<p>Simon Weinberg, a solicitor in the Commercial/IP/IT department at Matthew Arnold &amp; Baldwin LLP, commented, “This case is a cautionary tale not to abuse powers that you might have under a contract. The High Court has made clear that service credits are a defensive right, not an offensive right, and, unless performance by the other party warrants it, excessive service credits will not be considered appropriate. A contractual party with the benefit of service credits needs to use their common sense when they impose service credits under the contract, unlike the Trust in this instance. The Trust seemed to completely disregard the duty of good faith and destroyed any commercial relationship it had with Medirest. Even if there is no specific duty of good faith within an agreement, such an aggressive stance is not advisable in any contractual relationship and is inevitable road to disagreement and possible litigation.”</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/high-court-good-faith-breach-medirest-nhs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>British Airways fined £58.5m for exchange of commercially sensitive information over fuel surcharges with Virgin Atlantic</title>
		<link>http://www.mablaw.com/2012/05/british-airways-virgin-atlantic-fuel-surcharge/</link>
		<comments>http://www.mablaw.com/2012/05/british-airways-virgin-atlantic-fuel-surcharge/#comments</comments>
		<pubDate>Thu, 03 May 2012 20:41:12 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Commercial Contracts]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[agreements]]></category>
		<category><![CDATA[anti-competition]]></category>
		<category><![CDATA[anti-competitive]]></category>
		<category><![CDATA[breach of competition law]]></category>
		<category><![CDATA[co-operation]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[commercial law]]></category>
		<category><![CDATA[commercially sensitive information]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Competition Act]]></category>
		<category><![CDATA[competition law]]></category>
		<category><![CDATA[competitor]]></category>
		<category><![CDATA[fine]]></category>
		<category><![CDATA[illegal]]></category>
		<category><![CDATA[leniency]]></category>
		<category><![CDATA[Office of Fair Trading]]></category>
		<category><![CDATA[OFT]]></category>
		<category><![CDATA[unenforceable]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19812</guid>
		<description><![CDATA[The Office of Fair Trading has fined British Airways £58.5m for exchanging commercially sensitive information with its competitor, Virgin Atlantic, between 2004 and 2006. The information exchange led to co-ordinated price increases for fuel surcharges to reflect the soaring fuel costs. The OFT granted Virgin Atlantic full immunity under its leniency programme. In addition, BA’s [...]]]></description>
			<content:encoded><![CDATA[<p>The Office of Fair Trading has fined British Airways £58.5m for exchanging commercially sensitive information with its competitor, Virgin Atlantic, between 2004 and 2006. The information exchange led to co-ordinated price increases for fuel surcharges to reflect the soaring fuel costs. The OFT granted Virgin Atlantic full immunity under its leniency programme. In addition, BA’s fine was reduced from the initial £121.5m expected in 2007, due to its excellent co-operation in this case. Despite the reduced fine, the OFT hopes that the high fines sends out a clear message that co-operating with competitors to the detriment of consumers will be treated harshly.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/british-airways-virgin-atlantic-fuel-surcharge/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Marathon data publication to be investigated by Information Commissioner’s Office</title>
		<link>http://www.mablaw.com/2012/05/marathon-data-protection-ico/</link>
		<comments>http://www.mablaw.com/2012/05/marathon-data-protection-ico/#comments</comments>
		<pubDate>Thu, 03 May 2012 20:40:16 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Data Protection & Privacy (Other Sectors)]]></category>
		<category><![CDATA[Data Providers]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Online]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[Websites]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[data breach]]></category>
		<category><![CDATA[data breaches]]></category>
		<category><![CDATA[data controller]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[data protection act]]></category>
		<category><![CDATA[Data Protection Act 1998]]></category>
		<category><![CDATA[data protection directive]]></category>
		<category><![CDATA[data protection laws]]></category>
		<category><![CDATA[Data Provider]]></category>
		<category><![CDATA[data security]]></category>
		<category><![CDATA[data subject]]></category>
		<category><![CDATA[database]]></category>
		<category><![CDATA[databases]]></category>
		<category><![CDATA[ICO]]></category>
		<category><![CDATA[Information Commissioner]]></category>
		<category><![CDATA[Information Commissioner's Office]]></category>
		<category><![CDATA[misuse of data]]></category>
		<category><![CDATA[On-line]]></category>
		<category><![CDATA[web]]></category>
		<category><![CDATA[web site content]]></category>
		<category><![CDATA[webistes]]></category>
		<category><![CDATA[Website]]></category>
		<category><![CDATA[website content]]></category>
		<category><![CDATA[websites]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19810</guid>
		<description><![CDATA[The London Marathon organisers are being investigated by the Information Commissioner’s Office after the names, email addresses and home addresses of all 38,000 participants in this year’s competition were published on their public web site. The UK’s data protection and privacy watchdog is considering whether a breach of the Data Protection Act took place and [...]]]></description>
			<content:encoded><![CDATA[<p>The London Marathon organisers are being investigated by the Information Commissioner’s Office after the names, email addresses and home addresses of all 38,000 participants in this year’s competition were published on their public web site. The UK’s data protection and privacy watchdog is considering whether a breach of the Data Protection Act took place and what any punishment should be. Under the Act, anyone who looks after personal data is responsible for taking appropriate technical and organisational measures against unauthorised or unlawful processing or accidental loss of the data. The ICO can issue fines for serious breaches of the Act for up to £500,000.</p>
<p>Paul Gershlick, a Partner at Matthew Arnold &amp; Baldwin LLP, comments: “In my view, these are breaches of the Act, but not really serious breaches. Considering the flagrant breaches of data protection laws carried out by some, it would be unfortunate if an organisation’s mistake that did not reveal very private categories of data went punished when it does so much good. However, it should still be a salutary lesson to always have regard to data protection laws.”</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/marathon-data-protection-ico/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The NPPF: A new planning era has begun…</title>
		<link>http://www.mablaw.com/2012/05/the-nppf-national-planning-policy-framework-planning-developers-sustainable-development/</link>
		<comments>http://www.mablaw.com/2012/05/the-nppf-national-planning-policy-framework-planning-developers-sustainable-development/#comments</comments>
		<pubDate>Wed, 02 May 2012 10:10:04 +0000</pubDate>
		<dc:creator>David Marsden</dc:creator>
				<category><![CDATA[Commercial Developers]]></category>
		<category><![CDATA[Commercial Development]]></category>
		<category><![CDATA[Commercial Property]]></category>
		<category><![CDATA[Construction]]></category>
		<category><![CDATA[Housing Trusts]]></category>
		<category><![CDATA[Joint Ventures]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Planners]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Plot Sales]]></category>
		<category><![CDATA[Residential Developers]]></category>
		<category><![CDATA[Upload-RealEstate]]></category>
		<category><![CDATA[brownfield]]></category>
		<category><![CDATA[developers]]></category>
		<category><![CDATA[green belt]]></category>
		<category><![CDATA[housing]]></category>
		<category><![CDATA[National Planning Policy Framework]]></category>
		<category><![CDATA[NPPF]]></category>
		<category><![CDATA[sustainable development]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19841</guid>
		<description><![CDATA[The Government has recently published its long-awaited National Planning Policy Framework (NPPF). The purpose of the NPPF is to streamline planning bureaucracy, by condensing 44 planning policy statements and guidance notes (and thousands of pages) into a single 59-page document. It also: 1. Contains the economic, environmental and social planning policies for England; 2. Sets [...]]]></description>
			<content:encoded><![CDATA[<p>The Government has recently published its long-awaited <a href="http://www.communities.gov.uk/documents/planningandbuilding/pdf/2116950.pdf">National Planning Policy Framework</a> (NPPF).</p>
<p>The purpose of the NPPF is to streamline planning bureaucracy, by condensing 44 planning policy statements and guidance notes (and thousands of pages) into a single 59-page document. It also:</p>
<p>1. Contains the economic, environmental and social planning policies for England;</p>
<p>2. Sets out the Government&#8217;s planning policies for England and how they are expected to be applied; and</p>
<p>3. Must be taken into account in the preparation of local and neighbourhood plans.</p>
<p>The central theme of the NPPF is the “presumption in favour of sustainable development.”</p>
<p>The definition of “sustainable development” has been expanded so that it now includes reference to the social and environmental benefits of development. It includes five “guiding principles” of sustainable development, as set out in the <em>UK Sustainable Development Strategy</em>: living within the planet&#8217;s environmental limits; ensuring a strong, healthy and just society; achieving a sustainable economy; promoting good governance; and using sound science responsibly.</p>
<p>The NPPF lists 12 key planning principles that should be taken into account in both plan-making and decision-taking. Planning should:</p>
<p>1. Be genuinely plan-led;</p>
<p>2. Not simply be about scrutiny;</p>
<p>3. Be pro-actively driven and support sustainable economic development;</p>
<p>4. Always seek to secure high quality design and a good standard of amenity;</p>
<p>5. Take account of the different roles and character of different areas;</p>
<p>6. Support the transition to a low carbon future in a changing climate;</p>
<p>7. Contribute to conserving and enhancing the natural environment and reducing pollution;</p>
<p>8. Encourage the effective use of land by re-using brownfield land;</p>
<p>9. Promote mixed use developments;</p>
<p>10. Conserve heritage assets;</p>
<p>11. Actively manage patterns of growth; and</p>
<p>12. Take account of and support local strategies to improve health, social and cultural wellbeing.</p>
<p><span style="text-decoration: underline;"><strong>Some key points</strong></span></p>
<p>1. The NPPF encourages the effective use of land by re-using land that has been previously developed (i.e brownfield land), provided that it is not of high environmental value;</p>
<p>2. Planning policies should be positive, promote competitive town centre environments and set out policies for the management and growth of town centres. The NPPF retains the &#8220;sequential approach&#8221; to planning applications for main town centre uses. This requires most central town centre sites to be developed for shops, leisure and offices before out-of-town sites. However, an exemption to the sequential approach is included for small scale rural offices or other small scale rural development;</p>
<p>3. Local Planning Authorities (LPAs) should identify and annually update a supply of sites sufficient to provide five years&#8217; worth of housing against their housing requirements, with an additional buffer of 5 per cent to ensure choice and competition in the market. Where there has been a history of persistent under-delivery of housing, LPAs should increase the buffer to 20 per cent to provide a realistic prospect of achieving the planned supply and to ensure choices and competition in the market for land. However, there is recognition that housing land supply can best be met through new settlements or extensions to existing towns and villages;</p>
<p>4. The NPPF continues to protect land designated as green belt. As with previous green belt policy, inappropriate development should not be approved except in special circumstances. New buildings within the green belt, subject to a limited number of exceptions, are inappropriate. It should be noted that renewable energy projects will often be inappropriate development, and in such cases, the developer will need to demonstrate very special circumstances if projects are to proceed; and</p>
<p>5. Transitional provisions have been introduced to give local authorities a 12 month reprieve (until 26 March 2013), provided that the local development plan does not conflict too much with the NPPF.</p>
<p><span style="text-decoration: underline;"><strong>The future</strong></span></p>
<p>It is absolutely clear that we have entered a new planning era, although it will be some time before we see its full effect. There will undoubtedly be a period of uncertainty while LPAs try to interpret and then apply the transitional provisions.</p>
<p>Through the NPPF, the Government is attempting to support employment and growth, whilst serving the interests of local communities and the environment by keeping the relevant checks and balances in place. Development powers have been transferred to local authorities, and local communities will be able to decide where new homes (and the infrastructure to support them) should be built.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/the-nppf-national-planning-policy-framework-planning-developers-sustainable-development/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Supreme Court provides guidance for employers on justifying a compulsory retirement age</title>
		<link>http://www.mablaw.com/2012/05/supreme-court-seldon-clarkson-wrigh-jakes-guidance-for-employers-on-justifying-a-compulsory-retirement-age/</link>
		<comments>http://www.mablaw.com/2012/05/supreme-court-seldon-clarkson-wrigh-jakes-guidance-for-employers-on-justifying-a-compulsory-retirement-age/#comments</comments>
		<pubDate>Wed, 02 May 2012 10:01:06 +0000</pubDate>
		<dc:creator>Michael Delaney</dc:creator>
				<category><![CDATA[Employee Incentives]]></category>
		<category><![CDATA[Employee Share Schemes]]></category>
		<category><![CDATA[Employees]]></category>
		<category><![CDATA[Employer helpline]]></category>
		<category><![CDATA[Employers]]></category>
		<category><![CDATA[Employment]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Employment]]></category>
		<category><![CDATA[Work Issues]]></category>
		<category><![CDATA[age discrimination]]></category>
		<category><![CDATA[Clarkson Wright and Jakes]]></category>
		<category><![CDATA[compulsory retirement]]></category>
		<category><![CDATA[employyes]]></category>
		<category><![CDATA[partners]]></category>
		<category><![CDATA[partnerships]]></category>
		<category><![CDATA[retirement]]></category>
		<category><![CDATA[Seldon]]></category>
		<category><![CDATA[Supreme Court]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19838</guid>
		<description><![CDATA[In a landmark ruling in Seldon v Clarkson Wright and Jakes, the Supreme Court has provided important guidance on the components needed to justify a compulsory retirement age (and in particular a mandatory retirement age contained within a partnership agreement.) Lesley Seldon was a partner at a law firm that had a policy of retiring [...]]]></description>
			<content:encoded><![CDATA[<p>In a landmark ruling in <em><span style="text-decoration: underline;">Seldon v Clarkson Wright and Jakes</span></em>, the Supreme Court has provided important guidance on the components needed to justify a compulsory retirement age (and in particular a mandatory retirement age contained within a partnership agreement.)</p>
<p>Lesley Seldon was a partner at a law firm that had a policy of retiring partners at 65. When Mr Seldon reached the age of 65, he was duly retired under the partnership deed.</p>
<p>However, Mr Seldon brought an unlawful age discrimination claim under regulation 17 of the <em>Employment Equality (Age) Regulations 2006</em>, which prohibits discrimination on the ground of age against partners.</p>
<p>At the subsequent hearing, the Employment Tribunal found that the law firm&#8217;s retirement policy was justified, stating that it was a proportionate means of pursuing the firm’s legitimate aims of:</p>
<p>1. Giving the firm’s younger associates an opportunity of reaching partnership within a reasonable timescale, thus giving them an incentive to remain with the firm;</p>
<p>2. Facilitating workforce planning, by giving reasonable expectations on when partnership vacancies would arise; and</p>
<p>3. Limiting the need to expel underperforming partners.  </p>
<p>Subsequent appeals by Mr Seldon to the Employment Appeals Tribunal and the Court of Appeal failed.</p>
<p>Mr Seldon appealed to the Supreme Court on the basis that it was wrong to use the same test for justification for both direct and indirect age discrimination (and the aims pursued by the firm did not justify direct age discrimination), and that the treatment had to be justified in relation to his case and not just the retirement policy in general.</p>
<p>The Supreme Court unanimously dismissed the appeal, but remitted the case to the Employment Tribunal on an outstanding issue to consider whether the choice of a mandatory age of 65 was a proportionate means of achieving the legitimate aims of the partnership.</p>
<p>The ruling means that an employer can set its own default retirement age; however, it must have a legitimate aim and be able to provide evidence to justify its means of achieving it.</p>
<p>Although the case provides some clarity for employers over the issue compulsory retirement, some uncertainty remains. The fact that the Supreme Court has remitted the issue of proportionality back to the Employment Tribunal means that, currently, the issue of when particular retirement ages are justified is still a grey area. The issue of what age (60, 65?) is a justifiable retirement age remains unresolved.</p>
<p><span style="text-decoration: underline;"><strong>Points to note</strong> </span></p>
<p>1. The ruling applies to compulsory retirement ages for all employees (and not just partners);</p>
<p>2. The employer will have to prove that there are problems with recruiting younger workers in the firm’s industry/sector (and that this is a direct result of retaining older workers);</p>
<p>3. The employer will have to show that its chosen mandatory retirement age has been set at a level that is appropriate and necessary to achieve the firm’s particular aim in question; and</p>
<p>4. The employer (or partnership) will have to carefully draft retirement policies that explain the need for a retirement age.</p>
<p>If you would like to discuss the implications of this ruling for your business, or anything else employment-related, please contact me at <a href="mailto:michael.delaney@mablaw.com">michael.delaney@mablaw.com</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/supreme-court-seldon-clarkson-wrigh-jakes-guidance-for-employers-on-justifying-a-compulsory-retirement-age/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Acas publishes guidance on dealing with mental illness at work</title>
		<link>http://www.mablaw.com/2012/05/acas-publishes-guidance-on-dealing-with-mental-illness-at-work/</link>
		<comments>http://www.mablaw.com/2012/05/acas-publishes-guidance-on-dealing-with-mental-illness-at-work/#comments</comments>
		<pubDate>Wed, 02 May 2012 09:54:55 +0000</pubDate>
		<dc:creator>Michael Delaney</dc:creator>
				<category><![CDATA[Employee Incentives]]></category>
		<category><![CDATA[Employee Share Schemes]]></category>
		<category><![CDATA[Employees]]></category>
		<category><![CDATA[Employer helpline]]></category>
		<category><![CDATA[Employers]]></category>
		<category><![CDATA[Employment]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Employment]]></category>
		<category><![CDATA[Work Issues]]></category>
		<category><![CDATA[Acas]]></category>
		<category><![CDATA[mental health]]></category>
		<category><![CDATA[mental illness]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19835</guid>
		<description><![CDATA[Acas has published new guidance on tackling mental illness at work. Mental ill-health has a huge detrimental effect on productivity: 91m work days are lost every year, costing businesses £30bn a year through lost production, recruitment and absence. Mental illness, including dementia, depression, bipolar disorder, obsessive compulsive disorder and schizophrenia, is classed as a disability [...]]]></description>
			<content:encoded><![CDATA[<p>Acas has published new <a href="http://www.acas.org.uk/media/pdf/j/i/Promoting_positive_mental_health_at_work_JAN_2012.pdf">guidance</a> on tackling mental illness at work.</p>
<p>Mental ill-health has a huge detrimental effect on productivity: 91m work days are lost every year, costing businesses £30bn a year through lost production, recruitment and absence.</p>
<p>Mental illness, including dementia, depression, bipolar disorder, obsessive compulsive disorder and schizophrenia, is classed as a disability (at the point of diagnosis) under the <em>Equality Act 2010</em>, making it unlawful for an employer to treat a disabled person less favourably for a reason relating to their disability, without a justifiable reason.</p>
<p>It therefore makes good sense for an employer to take steps to understand and addressing mental health in the workplace.</p>
<p>This step-by-step guide intends to shows employers and managers how to:</p>
<p>1. Spot early the signs of mental ill-health;</p>
<p>2. Raise awareness of mental health issues among managers and staff;</p>
<p>3. Develop a culture where an employee feels comfortable disclosing their condition;</p>
<p>4. Approach an employee who may have a mental health condition; and</p>
<p>5. Try to help the employee cope with their condition or overcome it so they can work effectively again.</p>
<p>If you are unsure whether your workplace equality policies sufficiently cover mental illnesses, please contact me at <a href="mailto:michael.delaney@mablaw.com">michael.delaney@mablaw.com</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/acas-publishes-guidance-on-dealing-with-mental-illness-at-work/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New cookie law to be enforced from 26th May</title>
		<link>http://www.mablaw.com/2012/05/new-cookie-law-to-be-enforced-from-26th-may/</link>
		<comments>http://www.mablaw.com/2012/05/new-cookie-law-to-be-enforced-from-26th-may/#comments</comments>
		<pubDate>Tue, 01 May 2012 11:22:19 +0000</pubDate>
		<dc:creator>Simon Weinberg</dc:creator>
				<category><![CDATA[Data Protection & Privacy (Other Sectors)]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Online]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[Websites]]></category>
		<category><![CDATA[cookies]]></category>
		<category><![CDATA[cookies consent]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[data protection act]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[European Commission]]></category>
		<category><![CDATA[European Union]]></category>
		<category><![CDATA[flash cookies]]></category>
		<category><![CDATA[ICO]]></category>
		<category><![CDATA[illegal]]></category>
		<category><![CDATA[Information Commissioner's Office]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[online content]]></category>
		<category><![CDATA[personal data]]></category>
		<category><![CDATA[privacy]]></category>
		<category><![CDATA[Privacy and Electronic Communications (EC Directive) (Amendment) Regulations 2011]]></category>
		<category><![CDATA[unauthorised]]></category>
		<category><![CDATA[unlawful]]></category>
		<category><![CDATA[web]]></category>
		<category><![CDATA[web site]]></category>
		<category><![CDATA[web sites]]></category>
		<category><![CDATA[Website]]></category>
		<category><![CDATA[website content]]></category>
		<category><![CDATA[websites]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19819</guid>
		<description><![CDATA[The Privacy and Electronic Communications (EC Directive) (Amendment) Regulations 2011 will be enforced by the Information Commissioner’s Office from 26 May 2012. The Regulations require website operators to obtain consent of their users when placing cookies or locally stored objects (such as flash cookies) on those users’ devices (such as a computer or mobile phone). [...]]]></description>
			<content:encoded><![CDATA[<p>The Privacy and Electronic Communications (EC Directive) (Amendment) Regulations 2011 will be enforced by the Information Commissioner’s Office from 26 May 2012. The Regulations require website operators to obtain consent of their users when placing cookies or locally stored objects (such as flash cookies) on those users’ devices (such as a computer or mobile phone). Until the Regulations came into law in May 2011, the law had only required users to be given a statement describing the cookies, their use and how to disable them.</p>
<p>It will no longer be enough to obtain consent automatically on a general basis through a user’s browser; other steps will be needed. This has led to concerns as to how it will affect the user-friendliness of sites. But the law is clear – consent is needed. How to show consent is not clearly set out in the new law. The Information Commissioner’s Office has provided some guidance with suggestions. The type of consent the user must give will vary according to what the cookie contains, at what point in the process it is placed and also according to what the user may already have agreed to. <a href="http://www.ico.gov.uk/for_organisations/privacy_and_electronic_communications/the_guide/~/media/documents/library/Privacy_and_electronic/Practical_application/guidance_on_the_new_cookies_regulations.ashx">See the guidance here</a>. However, despite the guidance being updated in late 2011, it does not give totally definitive answers.</p>
<p>We have already been advising clients on how to comply with this new law and have come up with some practical suggestions of our own. If you would like to obtain our advice, please contact us on <a href="mailto:mark.weston@mablaw.com">mark.weston@mablaw.com</a> or <a href="mailto:paul.gershlick@mablaw.com">paul.gershlick@mablaw.com</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/new-cookie-law-to-be-enforced-from-26th-may/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Jet2 successful in its endeavours against Blackpool Airport &#8211; Jet2.com Ltd v Blackpool Airport Ltd, Court of Appeal</title>
		<link>http://www.mablaw.com/2012/05/jet2-blackpool-airport-court-appeal-endeavours/</link>
		<comments>http://www.mablaw.com/2012/05/jet2-blackpool-airport-court-appeal-endeavours/#comments</comments>
		<pubDate>Tue, 01 May 2012 11:12:13 +0000</pubDate>
		<dc:creator>Simon Weinberg</dc:creator>
				<category><![CDATA[Commercial Contracts]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[all reasonable endeavours]]></category>
		<category><![CDATA[best endeavours]]></category>
		<category><![CDATA[Blackpool Airport]]></category>
		<category><![CDATA[budget airlines]]></category>
		<category><![CDATA[commercial agreement]]></category>
		<category><![CDATA[Commercial contract]]></category>
		<category><![CDATA[commercial contracts]]></category>
		<category><![CDATA[contract]]></category>
		<category><![CDATA[contract law]]></category>
		<category><![CDATA[contracts]]></category>
		<category><![CDATA[Court of Appeal]]></category>
		<category><![CDATA[High Court]]></category>
		<category><![CDATA[Jet2]]></category>
		<category><![CDATA[low-cost airlines]]></category>
		<category><![CDATA[reasonable endeavours]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19814</guid>
		<description><![CDATA[Last year, the High Court considered a dispute between Blackpool Airport and Jet2, the low-cost airline, over the meaning of “all reasonable endeavours” in a contract between them. The dispute related to provisions in the contract that stated that Blackpool Airport (BAL) had to use all reasonable endeavours to provide a low cost base for [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.mablaw.com/2011/07/all-reasonable-endeavours-interests-jet2/">Last year, the High Court considered a dispute between Blackpool Airport and Jet2, the low-cost airline, over the meaning of “all reasonable endeavours” in a contract between them</a>. The dispute related to provisions in the contract that stated that Blackpool Airport (BAL) had to use all reasonable endeavours to provide a low cost base for Jet2, and under which both parties had agreed to use best endeavours to promote Jet2’s low cost services from BAL. Both parties agreed that “best endeavours” should be read to mean “all reasonable endeavours” for the purposes of this case. This is not always the case. The meaning of those respective phrases depends on the context.</p>
<p>The contract did not specify the operating hours of the airport. Initially, the airport opened or stayed open outside of its published operating hours for early or late flights respectively, as it seemed common ground between the parties that Jet2 needed flexibility to operate. However, BAL made an operating loss over that period and, after four years, refused to accept flights that were scheduled for arrival or departure outside of its published operating hours, giving Jet2 just one week to comply.</p>
<p>Jet2 issued proceedings against BAL for breach of contract. BAL argued that its ”all reasonable endeavours” obligation did not oblige it to act against its own commercial interests – i.e. to allow the flights to continue to run outside of its operating hours despite the airport making a loss as a result.</p>
<p><a href="http://www.bailii.org/ew/cases/EWHC/Comm/2011/1529.html">The High Court ruled</a> that BAL had breached the agreement, rejecting BAL’s justification of protection of its commercial interests. The High Court ruled that the initial intention of the parties in the agreement could not have been for BAL to change what it did on an on-going basis based on what profit it was making as a whole – this profit was affected not just by Jet2’s flights, but also by a number of other problems it faced. The High Court stated that those other problems should have been considered in a risk assessment by BAL before entering the agreement, and did not justify BAL restricting or stopping performance of its obligations under the agreement if it became unprofitable.</p>
<p><a href="http://www.bailii.org/cgi-bin/markup.cgi?doc=/ew/cases/EWCA/Civ/2012/417.html&amp;query=Jet2&amp;method=boolean">The Court of Appeal has recently upheld the High Court’s ruling</a>. In doing so, the Court of Appeal has highlighted that, in interpreting “endeavours” clauses, courts should consider whether the clauses have sufficiently clear objective criteria to place obligations on the parties. Otherwise, they could be unenforceable. The Court of Appeal ruled that the relevant clauses in this particular contract were sufficiently certain, although one of the judges did dissent from this view. The Court of Appeal also agreed that BAL’s losses, which it used as evidence to support its decision to stop flights running outside of operating hours, was not enough to justify its actions; rather, the Court of Appeal said that if it had become obvious that Jet2 could never operate profitably from Blackpool Airport, BAL would have been justified in not spending more money to promote it.</p>
<p>Simon Weinberg, a solicitor in the Commercial/IP/IT team at Matthew Arnold &amp; Baldwin LLP, commented, “This ruling highlights several points for commercial parties to consider when looking to include endeavours clauses in a legal agreement between them. The first is that, whilst endeavours clauses are useful, it is often much better to insert fixed obligations in the contract; although this is sometimes difficult, it is much more certain for the parties in interpreting their obligations going forward.</p>
<p>“The second is that, whilst it is understood that best endeavours usually means a party has to incur some cost in performing its obligations in order to comply, it is a question of fact in each instance. Here, BAL had breached the best endeavours clause but the Court of Appeal set out a situation where BAL would have been justified in its actions.</p>
<p>“Finally, this case again shows the need for legal advice in negotiating and drafting a commercial agreement; neither of the parties in this case received significant legal advice and it has since cost them substantial amounts in time and money to get to this point. Good lawyers will help to avoid problems of interpretation in contracts in the long term by drafting an agreement with clarity whilst also understanding the commercial reality of what the parties are trying to achieve.”</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/05/jet2-blackpool-airport-court-appeal-endeavours/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>At least 1 in 10 second hand hard drives still contain personal information and half contain some information</title>
		<link>http://www.mablaw.com/2012/04/second-hand-hard-drives-personal-information/</link>
		<comments>http://www.mablaw.com/2012/04/second-hand-hard-drives-personal-information/#comments</comments>
		<pubDate>Wed, 25 Apr 2012 08:14:28 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Data Protection & Privacy (Other Sectors)]]></category>
		<category><![CDATA[IT]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[breach of confidentiality]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[commercially sensitive information]]></category>
		<category><![CDATA[confidential information]]></category>
		<category><![CDATA[confidentiality]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[data breach]]></category>
		<category><![CDATA[data breaches]]></category>
		<category><![CDATA[data controller]]></category>
		<category><![CDATA[data destruction]]></category>
		<category><![CDATA[data erasure]]></category>
		<category><![CDATA[data loss]]></category>
		<category><![CDATA[data processor]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[data protection act]]></category>
		<category><![CDATA[Data Protection Act 1998]]></category>
		<category><![CDATA[data protection laws]]></category>
		<category><![CDATA[Data Provider]]></category>
		<category><![CDATA[data security]]></category>
		<category><![CDATA[data theft]]></category>
		<category><![CDATA[databases]]></category>
		<category><![CDATA[DPA]]></category>
		<category><![CDATA[ICO]]></category>
		<category><![CDATA[information]]></category>
		<category><![CDATA[Information Commissioner]]></category>
		<category><![CDATA[Information Commissioner's Office]]></category>
		<category><![CDATA[Intellectual property]]></category>
		<category><![CDATA[intellectual property rights]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[personal data]]></category>
		<category><![CDATA[sensitive personal data]]></category>
		<category><![CDATA[trade secret]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19806</guid>
		<description><![CDATA[11% of 200 hard drives bought second-hand from eBay and other locations in an investigation by the Information Commissioner’s Office contained personal data. Half of all of the drives contained some information on it. The personal data included scanned bank statements, passports, information on previous driving offences and some medical details. Four of the hard [...]]]></description>
			<content:encoded><![CDATA[<p>11% of 200 hard drives bought second-hand from eBay and other locations in an investigation by the Information Commissioner’s Office contained personal data. Half of all of the drives contained some information on it. The personal data included scanned bank statements, passports, information on previous driving offences and some medical details. Four of the hard drives had originated from organisations rather than individuals and they contained commercially sensitive information about the business, such as employees and customers.</p>
<p>Another survey by the UK’s data protection regulator showed that 1 in 10 people had admitted to not deleting data from mobile phones, computers or laptops. In addition, 65% hand on their old phones, computers and laptops to another user, with 44% giving it away to somebody else for free and around one in five (21%) selling it to somebody else.</p>
<p>The Information Commissioner, Christopher Graham, said: &#8220;We live in a world where personal and company information is a highly valuable commodity. It is important that people do everything they can to stop their details from falling into the wrong hands.&#8221;</p>
<p>Paul Gershlick, a Partner at Matthew Arnold &amp; Baldwin LLP, comments: “The results of the survey are surprising only in the sense that they are not worse. Many individuals and businesses either do not wipe data properly before dumping or selling them or fail to do so or use appropriate service providers who carry out this function properly. Businesses which fail to properly erase their data to a high enough standard could find that they are not only in breach of the Data Protection Act, but their valuable trade secrets are then used by competitors, possibly without their knowledge. For more information on what to do to comply with the law and protect your valuable assets, please contact me.”</p>
<p>For more on the ICO surveys, click here: <a href="http://www.ico.gov.uk/news/latest_news/2012/ico-report-finds-people-becoming-a-soft-touch-for-online-fraudsters-25042012.aspx">http://www.ico.gov.uk/news/latest_news/2012/ico-report-finds-people-becoming-a-soft-touch-for-online-fraudsters-25042012.aspx</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/second-hand-hard-drives-personal-information/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Regulators’ body advises that consent needed for use of image recognition technology</title>
		<link>http://www.mablaw.com/2012/04/article-29-working-party-image-recognition-technology/</link>
		<comments>http://www.mablaw.com/2012/04/article-29-working-party-image-recognition-technology/#comments</comments>
		<pubDate>Tue, 24 Apr 2012 14:40:55 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Data Protection & Privacy (Other Sectors)]]></category>
		<category><![CDATA[Data Providers]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Online]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[Websites]]></category>
		<category><![CDATA[Article 29]]></category>
		<category><![CDATA[Article 29 Working Party]]></category>
		<category><![CDATA[consent]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[data controller]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[data protection act]]></category>
		<category><![CDATA[Data Protection Act 1998]]></category>
		<category><![CDATA[data protection directive]]></category>
		<category><![CDATA[data protection laws]]></category>
		<category><![CDATA[Data Provider]]></category>
		<category><![CDATA[data security]]></category>
		<category><![CDATA[data subject]]></category>
		<category><![CDATA[data subject access]]></category>
		<category><![CDATA[DPA]]></category>
		<category><![CDATA[facial recognition technology]]></category>
		<category><![CDATA[necessary]]></category>
		<category><![CDATA[On-line]]></category>
		<category><![CDATA[online content]]></category>
		<category><![CDATA[personal data]]></category>
		<category><![CDATA[secure]]></category>
		<category><![CDATA[security]]></category>
		<category><![CDATA[social network]]></category>
		<category><![CDATA[social networking]]></category>
		<category><![CDATA[social networking site]]></category>
		<category><![CDATA[social networking website]]></category>
		<category><![CDATA[social networks]]></category>
		<category><![CDATA[web]]></category>
		<category><![CDATA[web site]]></category>
		<category><![CDATA[web site content]]></category>
		<category><![CDATA[web sites]]></category>
		<category><![CDATA[Website]]></category>
		<category><![CDATA[website content]]></category>
		<category><![CDATA[websites]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19782</guid>
		<description><![CDATA[The Article 29 Working Party has advised that social networking sites such as Facebook should get specific consent from users before suggesting to other users that photos those subsequent users are uploading to the site feature those users (providing the consent) by using facial recognition technology. Therefore, users who have not specifically consented to this [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://ec.europa.eu/justice/data-protection/article-29/documentation/opinion-recommendation/files/2012/wp192_en.pdf">The Article 29 Working Party has advised that social networking sites such as Facebook should get specific consent from users before suggesting to other users that photos those subsequent users are uploading to the site feature those users (providing the consent) by using facial recognition technology</a>. Therefore, users who have not specifically consented to this technology and individuals who are not registered with the site will not have their names suggested to the photo uploaders. The Article 29 Working Party is made up of representatives of data protection regulators of each member state of the European Union.</p>
<p>Social networking sites can process the photos without breaching data protection law if that processing is being done to check whether consent has been obtained, but, once that check has been finalised, the site must delete that information.</p>
<p>Facebook currently uses facial recognition technology to suggest the names of people featured in photographs to the uploaders. The name tags used by the uploaders can be viewed by other Facebook users.</p>
<p>Aside from consent, the Article 29 Working Party said that the social networking sites would need to take adequate technical measures such as encryption while the images are being uploaded. They should also use technical controls to try to safeguard against the images being used by third parties for purposes for which the user had not consented. To add to the regulatory burden, the body added that compliance with EU data protection law also meant giving the data subjects sufficient access rights to their images and not storing more data than was necessary for the tagging purpose.</p>
<p>The Working Party’s opinion also included some comments on the use of facial recognition technology by search engine providers and gaming services.</p>
<p>The Opinion is not legally binding, but it is best practice to comply with it, particularly as it gives an indication as to the action that the regulators would take to enforce the law.</p>
<p>Paul Gershlick, a Partner at Matthew Arnold &amp; Baldwin LLP, comments: “The Working Party has once again taken a strict pro-privacy stance in providing an opinion. This is similar to the tough line it took against social networking sites and others in its opinion last year on geo-location services. For more on that geo-location opinion, click here: <a href="http://www.mablaw.com/2011/06/article-29-working-party-geo-location-data/">http://www.mablaw.com/2011/06/article-29-working-party-geo-location-data/</a>.”</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/article-29-working-party-image-recognition-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ICO says publication of Operation Motorman files is a likely breach of the DPA</title>
		<link>http://www.mablaw.com/2012/04/ico-operation-motorman-files-publication/</link>
		<comments>http://www.mablaw.com/2012/04/ico-operation-motorman-files-publication/#comments</comments>
		<pubDate>Tue, 24 Apr 2012 14:40:12 +0000</pubDate>
		<dc:creator>Simon Weinberg</dc:creator>
				<category><![CDATA[Data Protection & Privacy (Other Sectors)]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[blagging]]></category>
		<category><![CDATA[data protection law]]></category>
		<category><![CDATA[data protection regulator]]></category>
		<category><![CDATA[Guido Fawkes]]></category>
		<category><![CDATA[ICO]]></category>
		<category><![CDATA[illegal]]></category>
		<category><![CDATA[Information Commissioner's Office]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[journalism]]></category>
		<category><![CDATA[journalists]]></category>
		<category><![CDATA[Leveson enquiry]]></category>
		<category><![CDATA[Operation Motorman]]></category>
		<category><![CDATA[Paul Staines]]></category>
		<category><![CDATA[personal data]]></category>
		<category><![CDATA[privacy]]></category>
		<category><![CDATA[unauthorised]]></category>
		<category><![CDATA[unlawful]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19797</guid>
		<description><![CDATA[The Information Commissioner’s Office (ICO), the UK’s data protection regulator, has condemned the publication online of records recovered during an investigation called “Operation Motorman”. Operation Motorman was an investigation into private investigators and the practice of “blagging” information for stories, which was started in 2002 by the ICO; blagging is obtaining personal data through deceit [...]]]></description>
			<content:encoded><![CDATA[<p>The Information Commissioner’s Office (ICO), the UK’s data protection regulator, has condemned the publication online of records recovered during an investigation called “Operation Motorman”. Operation Motorman was an investigation into private investigators and the practice of “blagging” information for stories, which was started in 2002 by the ICO; blagging is obtaining personal data through deceit and is a criminal offence under the Data Protection Act 1998.</p>
<p>Paul Staines, who runs the “Guido Fawkes” political blog, published the “Blue Book” section of the files from Operation Motorman, which included a list of journalists who had instructed private investigators on blagging assignments and the instructions those journalists allegedly gave.</p>
<p>The ICO said that Staines’ actions were “irresponsible” and potentially themselves also a breach of data protection laws. It has also said that those concerned that they were victims of blagging in relation to Operation Motorman could contact the ICO for a fast-tracked data subject access request. In addition, the on-going Leveson inquiry into press standards was considering the issue of publication.</p>
<p>Staines has defended his actions by claiming that the publication will help victims of blagging to take action against offenders and that it was in the public interest, a potential defence under the Act to the unlawful obtaining, disclosing or procuring of personal data. However, not all of the journalists on the list may have necessarily committed an offence.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/ico-operation-motorman-files-publication/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Jaguar not stopped from terminating distribution agreement without cause based on alleged pre-contract meeting discussions – Ghanem Al-Thani Holdings v Jaguar, High Court</title>
		<link>http://www.mablaw.com/2012/04/jaguar-ghanem-termination-distribution-agreement/</link>
		<comments>http://www.mablaw.com/2012/04/jaguar-ghanem-termination-distribution-agreement/#comments</comments>
		<pubDate>Tue, 24 Apr 2012 14:39:36 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Commercial Contracts]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[commercial agreement]]></category>
		<category><![CDATA[commercial agreements]]></category>
		<category><![CDATA[Commercial contract]]></category>
		<category><![CDATA[commercial contracts]]></category>
		<category><![CDATA[commercial law]]></category>
		<category><![CDATA[contract]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[distribution agreement]]></category>
		<category><![CDATA[distributor]]></category>
		<category><![CDATA[High Court]]></category>
		<category><![CDATA[misrepresentation]]></category>
		<category><![CDATA[pre-contract warranty]]></category>
		<category><![CDATA[representation]]></category>
		<category><![CDATA[representations]]></category>
		<category><![CDATA[terminate]]></category>
		<category><![CDATA[termination]]></category>
		<category><![CDATA[without cause]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19779</guid>
		<description><![CDATA[Jaguar appointed Ghanem as its sole distributor in Qatar. Jaguar terminated the agreement without cause on 12 months’ notice, as it was entitled to do under the agreement. Ghanem argued that it had been reluctant to sign the agreement and had only been persuaded to sign based on a meeting held just before signing in [...]]]></description>
			<content:encoded><![CDATA[<p>Jaguar appointed Ghanem as its sole distributor in Qatar. Jaguar terminated the agreement without cause on 12 months’ notice, as it was entitled to do under the agreement. Ghanem argued that it had been reluctant to sign the agreement and had only been persuaded to sign based on a meeting held just before signing in which it alleged that Jaguar had promised not to terminate using the without cause provision until Ghanem had recouped its investment.</p>
<p>The High Court has dismissed that argument. It argued that no promissory warranty or misrepresentation applied on the facts. It stretched belief to suggest that an issue such as that would not have been reflected in an updated draft of the agreement or a side letter. There was not even a note of the meeting. Ghanem’s position was all the more unlikely given that its lawyer had been present at the meeting. The Court said that what had seemed to have happened was that Ghanem had been under a misapprehension based on what it had wanted to happen and it had been comforted by what Jaguar said that it did in practice. However, that was not the same thing as saying that Jaguar had made a legally binding promise.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/jaguar-ghanem-termination-distribution-agreement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Internet filtering law to restrict access to pornographic material proposed</title>
		<link>http://www.mablaw.com/2012/04/internet-filtering-law-restrict-pornographic-access/</link>
		<comments>http://www.mablaw.com/2012/04/internet-filtering-law-restrict-pornographic-access/#comments</comments>
		<pubDate>Tue, 24 Apr 2012 14:38:47 +0000</pubDate>
		<dc:creator>Simon Weinberg</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Online]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[Websites]]></category>
		<category><![CDATA[bill]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[Internet service provider]]></category>
		<category><![CDATA[ISP]]></category>
		<category><![CDATA[mobile devices]]></category>
		<category><![CDATA[online content]]></category>
		<category><![CDATA[Online Safety Bill]]></category>
		<category><![CDATA[parliament]]></category>
		<category><![CDATA[pornographic material]]></category>
		<category><![CDATA[web]]></category>
		<category><![CDATA[web site]]></category>
		<category><![CDATA[web sites]]></category>
		<category><![CDATA[Website]]></category>
		<category><![CDATA[website blocking]]></category>
		<category><![CDATA[website content]]></category>
		<category><![CDATA[websites]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19795</guid>
		<description><![CDATA[A new Bill proposed to Parliament, if approved, would oblige Internet service providers (ISPs) to prevent customers from accessing pornographic images unless those customers have specifically notified the ISP that they want to access that material. The Online Safety Bill would require ISPs to provide a “default” service to customers that would exclude pornographic images, [...]]]></description>
			<content:encoded><![CDATA[<p>A new Bill proposed to Parliament, if approved, would oblige Internet service providers (ISPs) to prevent customers from accessing pornographic images unless those customers have specifically notified the ISP that they want to access that material. The <a href="http://www.publications.parliament.uk/pa/bills/lbill/2010-2012/0137/lbill_2010-20120137_en_1.htm">Online Safety Bill</a> would require ISPs to provide a “default” service to customers that would exclude pornographic images, so that if a customer wanted access they would need to be over eighteen and specifically opt-in. Even then, the ISPs would only be able to allow access if the specific website has an age verification policy in place.</p>
<p>The proposed law would also require manufacturers of devices that can access the Internet (including mobile phones) to ensure that those devices have filtering functionality installed.</p>
<p>ISPs have criticised the proposed law over concerns that it would lead to over-blocking and also because it leaves open the question as to who decides what is and what is not pornographic.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/internet-filtering-law-restrict-pornographic-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>3D printer development may lead to make-your-own medicines</title>
		<link>http://www.mablaw.com/2012/04/3d-printer-medicine-glasgow-university/</link>
		<comments>http://www.mablaw.com/2012/04/3d-printer-medicine-glasgow-university/#comments</comments>
		<pubDate>Thu, 19 Apr 2012 10:46:10 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[IT]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[3D printer]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[hardware]]></category>
		<category><![CDATA[life sciences]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19789</guid>
		<description><![CDATA[Glasgow University is pioneering the use of technology in which 3D printers are used to create drugs. Ultimately, they expect the technology to be used in customised drugs. The researchers said they are taking chemical constituents, passing them through a printer and creating a chemical synthesiser in which the reaction occurs allowing the operator to [...]]]></description>
			<content:encoded><![CDATA[<p>Glasgow University is pioneering the use of technology in which 3D printers are used to create drugs. Ultimately, they expect the technology to be used in customised drugs. The researchers said they are taking chemical constituents, passing them through a printer and creating a chemical synthesiser in which the reaction occurs allowing the operator to get out something different at the end. Therefore, when the process is completed, pharmaceutical companies or even individuals will be able to buy common chemicals, slot them into something that 3D prints, just press a button to mix the ingredients and filter them through the architecture and at the bottom would turn out the drug. It may sound too futuristic to be true, but the future will become true. 3D printing technology is already being used and further developed – this is just a mind-blowing logical development.</p>
<p>There is still a fair bit to do to bring this to market. The next step is for the scientists to switch ingredients and replicate drugs already available in pharmacies. They also hope to work with engineers to increase the printer&#8217;s speed and resolution. And then there will be the regulatory side to worry about given that people will be able to download recipes and print out their own medicines. The scientists say this will revolutionise healthcare when it becomes a reality, and it is not hard to see why.</p>
<p>Print out your own drugs, anyone?!</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/3d-printer-medicine-glasgow-university/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>OECD applauds UK for improvement in bribery laws, but says more must be done on enforcement against foreign corruption</title>
		<link>http://www.mablaw.com/2012/04/oecd-corruption-bribery-act/</link>
		<comments>http://www.mablaw.com/2012/04/oecd-corruption-bribery-act/#comments</comments>
		<pubDate>Thu, 19 Apr 2012 10:45:52 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Commercial Contracts]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[Wholesalers]]></category>
		<category><![CDATA[bribery]]></category>
		<category><![CDATA[Bribery Act]]></category>
		<category><![CDATA[Bribery Act 2010]]></category>
		<category><![CDATA[Bribery and Corruption]]></category>
		<category><![CDATA[OECD]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19777</guid>
		<description><![CDATA[The Organisation for Economic Co-operation and Development has praised the UK for having much improved anti-bribery and corruption laws following the high-profile introduction of the Bribery Act 2010. One of the key drivers behind the new law was to ensure that the UK complied with its international treaty obligations, so this news will be welcomed. [...]]]></description>
			<content:encoded><![CDATA[<p>The Organisation for Economic Co-operation and Development has praised the UK for having much improved anti-bribery and corruption laws following the high-profile introduction of the Bribery Act 2010. One of the key drivers behind the new law was to ensure that the UK complied with its international treaty obligations, so this news will be welcomed. However, the OECD did still have a couple of concerns: when settling foreign bribery-related cases, the UK authorities rely more on civil recovery orders that need less judicial oversight and are less transparent than criminal plea agreements; also, in some cases, the Serious Fraud Office has entered into confidentiality agreements which means that key information cannot be revealed after cases are settled. The OECD has required the UK to revert with oral submissions within one year and a written report within two years on the steps taken to address the OECD’s concerns.</p>
<p>Paul Gershlick, a Partner at Matthew Arnold &amp; Baldwin LLP, comments: “I have given quite a lot of training on the Bribery Act. The new legislation has taken the UK from having some of the most lenient legislation to the strictest anywhere in the world. For example, there is no defence to facilitation payments – routine payments made to local officials that enable organisations to do business in a particular country. It is therefore not surprising that the OECD has no problem with the new law. It is a concern, though, that it has raised issues surrounding its implementation. However, nearly a year after the law was implemented, we still await a high-profile public prosecution under the new regime.”</p>
<p>The report can be accessed here <a href="http://www.oecd.org/dataoecd/52/19/50026751.pdf">http://www.oecd.org/dataoecd/52/19/50026751.pdf</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/oecd-corruption-bribery-act/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Employment law: what changed in April 2012?</title>
		<link>http://www.mablaw.com/2012/04/employment-law-what-changed-in-april-2012-paternity-maternity-adoption-pay-sick-pay-apprenticeships-tribunals-unfair-dismissal/</link>
		<comments>http://www.mablaw.com/2012/04/employment-law-what-changed-in-april-2012-paternity-maternity-adoption-pay-sick-pay-apprenticeships-tribunals-unfair-dismissal/#comments</comments>
		<pubDate>Wed, 18 Apr 2012 16:08:46 +0000</pubDate>
		<dc:creator>Michael Delaney</dc:creator>
				<category><![CDATA[Employee Incentives]]></category>
		<category><![CDATA[Employee Share Schemes]]></category>
		<category><![CDATA[Employees]]></category>
		<category><![CDATA[Employer helpline]]></category>
		<category><![CDATA[Employers]]></category>
		<category><![CDATA[Employment]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Employment]]></category>
		<category><![CDATA[Work Issues]]></category>
		<category><![CDATA[apprenticeships]]></category>
		<category><![CDATA[costs]]></category>
		<category><![CDATA[costs awards]]></category>
		<category><![CDATA[deposit orders]]></category>
		<category><![CDATA[employee. employer]]></category>
		<category><![CDATA[employment tribunals]]></category>
		<category><![CDATA[qualifying period]]></category>
		<category><![CDATA[Statutory Adoption Pay]]></category>
		<category><![CDATA[Statutory Maternity Pay]]></category>
		<category><![CDATA[Statutory Paternity Pay]]></category>
		<category><![CDATA[Statutory Sick Pay]]></category>
		<category><![CDATA[unfair dismissal]]></category>
		<category><![CDATA[witness expenses]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19785</guid>
		<description><![CDATA[I have summarised below the main changes to employment law that took place on 1 and 6 April 2012. Statutory Maternity, Paternity and Adoption Pay 1. The standard rates of statutory maternity, paternity and adoption pay increase from £128.73 to £135.45 per week. The weekly earnings threshold for these payments rose from £102 to £107. [...]]]></description>
			<content:encoded><![CDATA[<p>I have summarised below the main changes to employment law that took place on 1 and 6 April 2012.</p>
<p><strong><span style="text-decoration: underline;">Statutory Maternity, Paternity and Adoption Pay</span></strong></p>
<p>1. The standard rates of statutory maternity, paternity and adoption pay increase from £128.73 to £135.45 per week. The weekly earnings threshold for these payments rose from £102 to £107.</p>
<p>2. Maternity allowance increased from £124.88 to £135.45, with the earnings threshold remaining at £30.</p>
<p><strong><span style="text-decoration: underline;">Statutory Sick Pay</span></strong></p>
<p>The standard rate of statutory sick pay increases from £81.60 to £85.85 per week.</p>
<p><strong><span style="text-decoration: underline;">Apprenticeships</span></strong></p>
<p>The <em>Apprenticeships (Form of Apprenticeship Agreement) Regulations 2012</em> prescribe the form of the apprenticeship agreement between an apprentice and an employer in England and Wales under s.32 of the <em>Apprenticeships, Skills, Children and Learning Act 2009</em>.</p>
<p>The Regulations state<em> </em>that apprenticeship agreements entered into under the <em>Apprenticeships, Skills, Children and Learning Act 2009</em> must contain the basic terms of employment required to be given to employees under section 1 of the <em>Employment Rights Act 1996</em>. This can be in the form of a written statement of particulars of employment, a written contract of employment or a letter of engagement.</p>
<p>The apprenticeship agreement must also include a statement of the skill, trade or occupation for which the apprentice is being trained under the relevant apprenticeship framework.</p>
<p>Under section 35 of the Apprenticeships, Skills, Children and Learning Act 2009, an apprenticeship agreement entered into under the Act has the status of a contract of service and not a contract of apprenticeship.</p>
<p><strong><span style="text-decoration: underline;">Employment tribunals</span> </strong></p>
<p>1. Deposit orders. The amount of deposit order an employment tribunal will be able to order a party to pay as a condition to continuing with tribunal proceedings has increased from £500 to £1,000.</p>
<p>2. Costs awards. The maximum amount of costs an employment tribunal can award in favour of a legally represented party (without referring the case to the county court for detailed assessment) has increased from £10,000 to £20,000.</p>
<p>3. Witness expenses. Employment tribunals now have the power to order parties to bear the costs of witness attendance; the party who loses the case will have to reimburse the successful party for any such costs that have already been paid out.</p>
<p><span style="text-decoration: underline;"><strong>Unfair dismissal</strong></span></p>
<p>The unfair dismissal qualifying period has increase from one to two years.</p>
<p>Employees whose employment commenced on or after 6 April 2012 will need two years’ service before accruing the right to claim unfair dismissal or becoming entitled to written reasons for dismissal.</p>
<p>The qualifying period will continue to be one year for those employees whose employment commenced before 6 April 2012.</p>
<p>If you have any concerns about these changes and how they will affect your business, or want to discuss anything else employment-related, please contact me at <a href="mailto:michael.delaney@mablaw.com">michael.delaney@mablaw.com</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/employment-law-what-changed-in-april-2012-paternity-maternity-adoption-pay-sick-pay-apprenticeships-tribunals-unfair-dismissal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>European Commission investigates whether Motorola refused to license essential patents on fair terms and abused dominant position</title>
		<link>http://www.mablaw.com/2012/04/european-commission-motorola-apple-microsof/</link>
		<comments>http://www.mablaw.com/2012/04/european-commission-motorola-apple-microsof/#comments</comments>
		<pubDate>Mon, 16 Apr 2012 15:25:18 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[Inventions]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[abuse]]></category>
		<category><![CDATA[abuse of dominance]]></category>
		<category><![CDATA[abuse of dominant position]]></category>
		<category><![CDATA[anti-competition]]></category>
		<category><![CDATA[anti-competitive]]></category>
		<category><![CDATA[anti-trust]]></category>
		<category><![CDATA[Article 102]]></category>
		<category><![CDATA[Article 82]]></category>
		<category><![CDATA[breach of competition law]]></category>
		<category><![CDATA[competition law]]></category>
		<category><![CDATA[EU competition law]]></category>
		<category><![CDATA[EU law]]></category>
		<category><![CDATA[European Union law]]></category>
		<category><![CDATA[fair]]></category>
		<category><![CDATA[fair reasonably and non-discriminatory]]></category>
		<category><![CDATA[FRAND terms]]></category>
		<category><![CDATA[non-discriminatory]]></category>
		<category><![CDATA[reasonable]]></category>
		<category><![CDATA[TFEU]]></category>
		<category><![CDATA[Treaty on the Functioning of the European Union]]></category>
		<category><![CDATA[unfair]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19775</guid>
		<description><![CDATA[The European Commission has opened up an investigation as to whether Motorola has abused its dominant position by allegedly refusing to fairly license its patents which were essential to other players in the industry based on the industry standards.  Those patents have to be licensed on fair, reasonable and non-discriminatory terms.  Microsoft and Apple have [...]]]></description>
			<content:encoded><![CDATA[<p>The European Commission has opened up an investigation as to whether Motorola has abused its dominant position by allegedly refusing to fairly license its patents which were essential to other players in the industry based on the industry standards.  Those patents have to be licensed on fair, reasonable and non-discriminatory terms.  Microsoft and Apple have alleged that Motorola has acted abusively by not offering fair licensing terms and seeking to enforce injunctions based on use of Motorola patents within their flagship products.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/european-commission-motorola-apple-microsof/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>£180m fund for SMEs in life sciences industry launched</title>
		<link>http://www.mablaw.com/2012/04/biomedical-catalyst-life-sciences-tsb/</link>
		<comments>http://www.mablaw.com/2012/04/biomedical-catalyst-life-sciences-tsb/#comments</comments>
		<pubDate>Mon, 16 Apr 2012 15:04:49 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[Inventions]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Biomedical Catalyst]]></category>
		<category><![CDATA[grant]]></category>
		<category><![CDATA[Intellectual property]]></category>
		<category><![CDATA[intellectual property rights]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[life sciences]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>
		<category><![CDATA[Technology Strategy Board]]></category>
		<category><![CDATA[TSB]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19767</guid>
		<description><![CDATA[The £180m fund for small and medium sized enterprises in the life sciences industry is being made available from 30 April, the Government has announced. Under the Biomedical Catalyst, the Medical Research Council and Technology Strategy Board will work together to provide the funds for three different stages of development with a maximum grant of £150,000 for feasibility, [...]]]></description>
			<content:encoded><![CDATA[<p>The £180m fund for small and medium sized enterprises in the life sciences industry is being made available from 30 April, the Government has announced. Under the Biomedical Catalyst, the Medical Research Council and Technology Strategy Board will work together to provide the funds for three different stages of development with a maximum grant of £150,000 for feasibility, and up to £3m for early stage and late stage. The fund will be used to support innovation ideas that &#8220;demonstrate the potential to provide significant positive healthcare and economic impact&#8221;.</p>
<p>The Prime Minister has said: &#8220;The UK boasts a world-leading life sciences sector which is changing at an incredible pace.  And I&#8217;m absolutely committed to helping it widen its significant foothold in the global market&#8221;.</p>
<p>More information on how to apply can be found here: <a href="http://www.innovateuk.org/content/competition/biomedical-catalyst.ashx">http://www.innovateuk.org/content/competition/biomedical-catalyst.ashx</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/biomedical-catalyst-life-sciences-tsb/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Knowledge of clear legal principles may be attributed to contractual parties in implying terms – Spencer v Secretary of State for Defence, High Court</title>
		<link>http://www.mablaw.com/2012/04/clear-legal-principles-implying-terms-high-court/</link>
		<comments>http://www.mablaw.com/2012/04/clear-legal-principles-implying-terms-high-court/#comments</comments>
		<pubDate>Mon, 16 Apr 2012 15:00:16 +0000</pubDate>
		<dc:creator>Simon Weinberg</dc:creator>
				<category><![CDATA[Commercial Contracts]]></category>
		<category><![CDATA[Commercial Property]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[commercial agreement]]></category>
		<category><![CDATA[Commercial contract]]></category>
		<category><![CDATA[commercial contracts]]></category>
		<category><![CDATA[contract]]></category>
		<category><![CDATA[contract law]]></category>
		<category><![CDATA[contracts]]></category>
		<category><![CDATA[contractual parties]]></category>
		<category><![CDATA[High Court]]></category>
		<category><![CDATA[implied terms]]></category>
		<category><![CDATA[imply]]></category>
		<category><![CDATA[omplied terms]]></category>
		<category><![CDATA[secretary of state for defence]]></category>
		<category><![CDATA[well-established legal principlies]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19772</guid>
		<description><![CDATA[In a ruling relating to the tenancy of agricultural land granted by the Secretary of State for Defence and whether the parties had agreed that a rental figure should be assessed on review, the High Court has ruled that, when deciding whether a provision should be implied into a contract, knowledge of clear and well-known [...]]]></description>
			<content:encoded><![CDATA[<p>In a ruling relating to the tenancy of agricultural land granted by the Secretary of State for Defence and whether the parties had agreed that a rental figure should be assessed on review, the High Court has ruled that, when deciding whether a provision should be implied into a contract, knowledge of clear and well-known legal principles may be attributed to the parties to that contract, even if the parties were not aware of those principles.</p>
<p>Attributing that knowledge to the parties allowed the High Court to imply a term. In this particular case, the High Court stated that if its ruling went any other way the tenant would receive a “windfall” that was not intended or expected, although the facts of this case were specific. The legal principle attributed to the parties here was that adding to the property covered by a tenancy would constitute the grant of a new lease. The High Court ruled that this was part of the knowledge available to the reasonable observer of the contract.</p>
<p>This ruling sets out a clear principle about implying terms into contracts in general – clear and well-established legal principles are attributed to the parties of a contract in deciding whether to imply a term into that contract.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/clear-legal-principles-implying-terms-high-court/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Evidence of patent cliff underway with 2011 fall in NHS drug spend</title>
		<link>http://www.mablaw.com/2012/04/patent-cliff-nhs-pharma/</link>
		<comments>http://www.mablaw.com/2012/04/patent-cliff-nhs-pharma/#comments</comments>
		<pubDate>Thu, 05 Apr 2012 17:10:19 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[Inventions]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[big pharma]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[invention]]></category>
		<category><![CDATA[National Health Service]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[patent]]></category>
		<category><![CDATA[patent cliff]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical patents]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19737</guid>
		<description><![CDATA[The first evidence has been emerging of the effects of the patent cliff, with NHS spending on pharmaceuticals falling from £8.83bn in 2010 to £8.81bn in 2011, according to figures from the NHS Information Centre.  Although only a small fall, this must be set against general annual rises of 3-4% each year.  And this is [...]]]></description>
			<content:encoded><![CDATA[<p>The first evidence has been emerging of the effects of the patent cliff, with NHS spending on pharmaceuticals falling from £8.83bn in 2010 to £8.81bn in 2011, according to figures from the NHS Information Centre.  Although only a small fall, this must be set against general annual rises of 3-4% each year.  And this is before the real effects of the patent cliff get underway.  The patent cliff is the falling out of patent of many of the big blockbuster drugs between 2011 and 2016 without sufficient drugs to replace them.  The 2011 figures do not take account of some of the biggest drugs that are just coming off patent and open to competition from much cheaper generics, such as Pfizer&#8217;s Lipitor, which cost the NHS more than £300m in 2011.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/patent-cliff-nhs-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Most GPs think Government reforms will not improve healthcare</title>
		<link>http://www.mablaw.com/2012/04/gps-government-reforms-healthcare-health-social-care/</link>
		<comments>http://www.mablaw.com/2012/04/gps-government-reforms-healthcare-health-social-care/#comments</comments>
		<pubDate>Thu, 05 Apr 2012 14:49:33 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[clinical commissioning groups]]></category>
		<category><![CDATA[GP]]></category>
		<category><![CDATA[health]]></category>
		<category><![CDATA[Health and Social Care Act]]></category>
		<category><![CDATA[Health and Social Care Bill]]></category>
		<category><![CDATA[healthcare]]></category>
		<category><![CDATA[life sciences]]></category>
		<category><![CDATA[National Health Service]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19707</guid>
		<description><![CDATA[55% of GPs think that the Government’s plans for commissioning of healthcare budgets to take place on a local level will not improve healthcare. Just 12% thought patients would see a noticeable improvement (down from 23% in 2010), with the remaining people unsure. These are the results of a BBC poll of 800 GPs. 87% [...]]]></description>
			<content:encoded><![CDATA[<p>55% of GPs think that the Government’s plans for commissioning of healthcare budgets to take place on a local level will not improve healthcare. Just 12% thought patients would see a noticeable improvement (down from 23% in 2010), with the remaining people unsure. These are the results of a BBC poll of 800 GPs. 87% of respondents also thought that private companies would have a larger role in the NHS under the reforms. A majority also thought that there would be more rationing in healthcare because of budgetary constraints.</p>
<p>This poll is a blow to the Government, which has used the justification of the need to pass power to GPs level as a reason for pressing ahead with the reforms, but it will also need the involvement and enthusiasm of GPs to make these changes work.</p>
<p>In April 2013, the Health and Social Care Act will hand control of about £60bn of the NHS budget in England to GPs clinical commissioning groups, which will be responsible for planning and buying most routine healthcare for their local community. The Government says the Act would hand power to GPs, put patients at the heart of the NHS, and reduce needless bureaucracy.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/gps-government-reforms-healthcare-health-social-care/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BCAP starts consultation on comparative advertising and amends distance selling rules for broadcast advertising</title>
		<link>http://www.mablaw.com/2012/04/bcap-consultation-comparative-advertising-amends-distance-selling-rules/</link>
		<comments>http://www.mablaw.com/2012/04/bcap-consultation-comparative-advertising-amends-distance-selling-rules/#comments</comments>
		<pubDate>Thu, 05 Apr 2012 14:49:10 +0000</pubDate>
		<dc:creator>Simon Weinberg</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[TV & Radio]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[BCAP]]></category>
		<category><![CDATA[BCAP Code]]></category>
		<category><![CDATA[Broadcast Committee on Advertising Practice]]></category>
		<category><![CDATA[CAP code]]></category>
		<category><![CDATA[comparative advertising]]></category>
		<category><![CDATA[comparative pricing]]></category>
		<category><![CDATA[Consumer Protection (Distance Selling) Regulations 2000]]></category>
		<category><![CDATA[distance selling]]></category>
		<category><![CDATA[misleading advertising]]></category>
		<category><![CDATA[VAT]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19723</guid>
		<description><![CDATA[The Broadcast Committee on Advertising Practice (BCAP) is responsible for writing and updating the UK Code of Broadcast Advertising (BCAP Code) with the aim of preventing broadcast advertising from being misleading, causing harm or offence and breaching boundaries of taste and decency. BCAP has recently announced two moves in relation to the BCAP Code, one being [...]]]></description>
			<content:encoded><![CDATA[<p>The Broadcast Committee on Advertising Practice (BCAP) is responsible for writing and updating the <a href="http://cap.org.uk/The-Codes/BCAP-Code.aspx">UK Code of Broadcast Advertising</a> (BCAP Code) with the aim of preventing broadcast advertising from being misleading, causing harm or offence and breaching boundaries of taste and decency. BCAP has recently announced two moves in relation to the BCAP Code, one being an amendment and the other a proposed amendment:</p>
<p>1)    <a href="http://www.bcap.org.uk/Media-Centre/2012/BCAP-amends-Distance-Selling-rules-in-the-UK-Code-of-Broadcast-Advertising-(BCAP-Code).aspx">The amendment of the distance selling rules in the BCAP Code</a></p>
<p>BCAP has announced that the distance selling rules in the BCAP Code are to be restricted to business-to-consumer advertisements. This change means that the distance selling rules in the BCAP Code fit in with the Consumer Protection (Distance Selling) Regulations 2000 and with the CAP Code (which restricts non-broadcast advertising). The change came into effect on 23 March.</p>
<p>2)    <a href="http://www.cap.org.uk/CAP-and-BCAP-Consultations/Open-consultations/~/media/Files/CAP/Consultations/BCAP%20Pricing%20consultation%20document%20%2023%20Mar%202012.ashx">Consultation on amending the comparative advertising and VAT rules in the BCAP Code</a></p>
<p>BCAP is proposing to remove the provisions of the BCAP Code that require comparative price claims to relate to identical or substantially similar products. This will allow advertisers more flexibility in comparative claims so that comparisons can be made between non-identical products that have the same function.</p>
<p>BCAP is also proposing to amend the rules relating to the inclusion of VAT in headline prices. The proposed amendment will mean that quoted prices should include mandatory taxes, duties, fees and charges that apply to most buyers, but that a VAT-exclusive price can be given if the price is addressed to an audience with no VAT liability or who can recover VAT. Those VAT-exclusive claims should, however, be accompanied by a clear statement of the rate of VAT payable.</p>
<p>The consultation is open until 4 May 2012.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/bcap-consultation-comparative-advertising-amends-distance-selling-rules/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>All Party Parliamentary Pharmacy Group hears conflicting points of view in enquiry over pharma supply chain shortage</title>
		<link>http://www.mablaw.com/2012/04/all-party-parliamentary-pharmacy-group-supply-chain/</link>
		<comments>http://www.mablaw.com/2012/04/all-party-parliamentary-pharmacy-group-supply-chain/#comments</comments>
		<pubDate>Thu, 05 Apr 2012 14:47:23 +0000</pubDate>
		<dc:creator>Paul Gershlick</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Wholesalers]]></category>
		<category><![CDATA[ABPI]]></category>
		<category><![CDATA[Assoication of the British Pharmaceutical Industry]]></category>
		<category><![CDATA[big pharma]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[pharma products]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmaceutical business]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[pharmaceutical market]]></category>
		<category><![CDATA[pharmaceutical products]]></category>
		<category><![CDATA[pharmaceutical sector]]></category>
		<category><![CDATA[pharmacies]]></category>
		<category><![CDATA[pharmacy]]></category>
		<category><![CDATA[supply chain]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19670</guid>
		<description><![CDATA[The All Party Parliamentary Pharmacy Group has heard conflicting evidence over the supply chain shortage that is afflicting the UK pharma industry.  On the one hand, the Association for British Pharmaceutical Industry &#8211; which predominantly represents big pharma companies &#8211; has called for a separation of pharmacists&#8217; wholesaling and dispensing activities to create more transparency. However, [...]]]></description>
			<content:encoded><![CDATA[<p>The All Party Parliamentary Pharmacy Group has heard conflicting evidence over the supply chain shortage that is afflicting the UK pharma industry.  On the one hand, the Association for British Pharmaceutical Industry &#8211; which predominantly represents big pharma companies &#8211; has called for a separation of pharmacists&#8217; wholesaling and dispensing activities to create more transparency. However, Earl Howe, the Pharmacy Minister, says that that would add to costs to small business and create legal risks. He has also said that there was no evidence that a legal requirement on drug manufacturers to supply within 24 hours of any request would resolve the problems being faced. He expressed frustration that there was a lack of evidence as to where the causes of the problems lie. He said that people on the supply chain had been consistently asked about anything that damaged patients&#8217; interests, but nothing had transpired.</p>
<p>The Group is holding an enquiry into the supply chain problems and is due to report back after Easter.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/all-party-parliamentary-pharmacy-group-supply-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ICO guidance released on identifying data controllers and processors and exemptions for regulators</title>
		<link>http://www.mablaw.com/2012/04/ico-guidance-identifying-data-controllers-processors-exemptions-regulators/</link>
		<comments>http://www.mablaw.com/2012/04/ico-guidance-identifying-data-controllers-processors-exemptions-regulators/#comments</comments>
		<pubDate>Thu, 05 Apr 2012 14:46:39 +0000</pubDate>
		<dc:creator>Simon Weinberg</dc:creator>
				<category><![CDATA[Data Protection & Privacy (Other Sectors)]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Upload-Commercial/IP/IT]]></category>
		<category><![CDATA[Upload-Pharma]]></category>
		<category><![CDATA[Upload-TMT]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[data controller]]></category>
		<category><![CDATA[data processor]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[data protection act]]></category>
		<category><![CDATA[Data Protection Act 1998]]></category>
		<category><![CDATA[ICO]]></category>
		<category><![CDATA[Information Commissioner's Office]]></category>
		<category><![CDATA[joint data controller]]></category>
		<category><![CDATA[personal data]]></category>
		<category><![CDATA[privacy]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[section 31 exemption]]></category>

		<guid isPermaLink="false">http://www.mablaw.com/?p=19721</guid>
		<description><![CDATA[The Information Commissioner’s Office has issued two sets of guidance, the first on how to identify a data controller or data processor under the Data Protection Act 1998 (DPA) and the second on the exemption provided to regulators under section 31 of the DPA. 1)    Guidance on identifying data controllers and data processors The [...]]]></description>
			<content:encoded><![CDATA[<p>The Information Commissioner’s Office has issued two sets of guidance, the first on how to identify a data controller or data processor under the Data Protection Act 1998 (DPA) and the second on the exemption provided to regulators under section 31 of the DPA.</p>
<p>1)    <a href="http://www.ico.gov.uk/for_organisations/guidance_index/~/media/documents/library/Data_Protection/Detailed_specialist_guides/data_controllers_and_data_processors.ashx">Guidance on identifying data controllers and data processors</a></p>
<p>The guidance focuses on the key issues to consider when determining who is a data controller or a data processor. The guidance makes it clear that it will not always be clear-cut and that there will be some instances where the line between data controller and data processor will be blurred.</p>
<p>For example, a data controller may be made up of two bodies acting jointly, usually a client and a service provider where the service provided is the processing of personal data. The client will usually be the data controller and the service provider the data processor, but the distinction is not as clear-cut where the service provider is given flexibility in carrying out the client’s instructions or where the service provider provides the service in accordance with externally imposed professional standards.</p>
<p>The guidance recognises that, where there is a joint data controller, there needs to be flexibility to allow for practical arrangements to be made to fulfil the data protection obligations of both; for example, one obligation can be taken on by only one of them provided that it reflects the reality of the relationship between the parties.</p>
<p>2)    <a href="http://www.ico.gov.uk/for_organisations/guidance_index/~/media/documents/library/Data_Protection/Detailed_specialist_guides/regulatory_activity_exemption_section_31_guidance.ashx">Guidance on the use of the section 31 exemption</a></p>
<p>Section 31 of the DPA can be used by regulatory bodies to withhold information requested or to be provided under the subject information provisions defined in section 27 of the DPA. The exemption applies where the application of the subject information provisions might prejudice the regulator’s discharge of its functions. The guidance makes clear that this test for this prejudice of its functions is a strict one.</p>
<p>The guidance adds that:</p>
<p>a)    the section 31 exemption cannot be used in relation to internal investigations or complaints handling functions; and</p>
<p>b)    where a business (such as a bank) supplies data to an ombudsman in relation to a customer complaint, as the ombudsman can rely on section 31 to resist a subject access request, the business can withhold data as if covered by section 31 even though it would not normally be covered.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mablaw.com/2012/04/ico-guidance-identifying-data-controllers-processors-exemptions-regulators/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

